| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.808 | 0.001 | 0.808 | Bcr-Abl kinase inhibitor | 0.649 0.002 DBMET00025 0.358 0.003 DBMET00026 0.328 0.004 DBMET00027 0.684 0.002 DBMET00028 0.499 0.002 DBMET03525 0.11 0.033 DBMET03527 0.528 0.002 DBMET03526 0.57 0.002 DBMET03528 0.432 0.003 DBMET03529 0.565 0.002 DBMET03530 0.494 0.002 DBMET03531 | ||
| 0.68 | 0.005 | 0.68 | MAP kinase 1 inhibitor | 0.638 0.012 DBMET00025 0.535 0.04 DBMET00026 0.563 0.031 DBMET00028 0.416 0.096 DBMET03525 0.614 0.017 DBMET03526 0.63 0.014 DBMET03528 0.54 0.039 DBMET03529 0.595 0.021 DBMET03530 0.603 0.02 DBMET03531 | ||
| 0.62 | 0.005 | 0.645 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.642 0.004 DBMET00025 0.424 0.081 DBMET00026 0.494 0.036 DBMET00027 0.51 0.029 DBMET00028 0.527 0.023 DBMET03525 0.525 0.024 DBMET03527 0.634 0.004 DBMET03526 0.557 0.014 DBMET03528 0.582 0.009 DBMET03529 0.589 0.008 DBMET03530 0.645 0.004 DBMET03531 | DBMET03531 | |
| 0.617 | 0.01 | 0.617 | Tyrosine kinase inhibitor | 0.587 0.012 DBMET00025 0.226 0.06 DBMET00026 0.44 0.023 DBMET00027 0.401 0.028 DBMET00028 0.254 0.053 DBMET03525 0.255 0.052 DBMET03527 0.434 0.024 DBMET03526 0.514 0.016 DBMET03528 0.477 0.02 DBMET03529 0.529 0.015 DBMET03530 0.493 0.018 DBMET03531 | ||
| 0.549 | 0.003 | 0.592 | Granulocyte macrophage colony stimulating factor antagonist | 0.48 0.004 DBMET00025 0.18 0.027 DBMET00026 0.592 0.003 DBMET00027 0.562 0.003 DBMET00028 0.333 0.006 DBMET03525 0.14 0.041 DBMET03527 0.192 0.024 DBMET03526 0.52 0.004 DBMET03528 0.432 0.004 DBMET03529 0.448 0.004 DBMET03530 0.449 0.004 DBMET03531 | DBMET00027 | |
| 0.539 | 0.023 | 0.581 | Angiogenesis inhibitor | 0.514 0.027 DBMET00025 0.35 0.071 DBMET00026 0.45 0.04 DBMET00027 0.489 0.032 DBMET00028 0.353 0.07 DBMET03525 0.247 0.126 DBMET03527 0.524 0.025 DBMET03526 0.581 0.019 DBMET03528 0.551 0.022 DBMET03529 0.535 0.024 DBMET03530 0.529 0.024 DBMET03531 | DBMET03528 | |
| 0.481 | 0.005 | 0.482 | Lck kinase inhibitor | 0.478 0.005 DBMET00025 0.21 0.036 DBMET00026 0.28 0.019 DBMET00027 0.371 0.01 DBMET00028 0.268 0.021 DBMET03525 0.126 0.081 DBMET03527 0.482 0.005 DBMET03526 0.423 0.007 DBMET03528 0.417 0.007 DBMET03529 0.416 0.007 DBMET03530 0.424 0.007 DBMET03531 | DBMET03526 | |
| 0.463 | 0.005 | 0.499 | Cytokine production inhibitor | 0.447 0.005 DBMET00025 0.177 0.045 DBMET00026 0.311 0.014 DBMET00028 0.201 0.036 DBMET03525 0.154 0.059 DBMET03527 0.499 0.004 DBMET03526 0.362 0.009 DBMET03528 0.343 0.01 DBMET03529 0.348 0.01 DBMET03530 0.405 0.006 DBMET03531 | DBMET03526 | |
| 0.462 | 0.008 | 0.462 | Src kinase inhibitor | 0.439 0.009 DBMET00025 0.201 0.054 DBMET00026 0.362 0.017 DBMET00027 0.365 0.016 DBMET00028 0.241 0.038 DBMET03525 0.186 0.062 DBMET03527 0.417 0.011 DBMET03526 0.407 0.012 DBMET03528 0.396 0.013 DBMET03529 0.369 0.016 DBMET03530 0.393 0.013 DBMET03531 | ||
| 0.476 | 0.025 | 0.489 | MAP kinase kinase 6 inhibitor | 0.489 0.021 DBMET00025 0.444 0.037 DBMET00026 0.39 0.065 DBMET00027 0.458 0.031 DBMET00028 0.467 0.028 DBMET03525 0.369 0.078 DBMET03527 0.435 0.04 DBMET03526 0.427 0.044 DBMET03528 0.44 0.038 DBMET03529 0.449 0.035 DBMET03530 0.482 0.023 DBMET03531 | DBMET00025 | |
| 0.448 | 0.005 | 0.448 | Protein-tyrosine kinase (PTK, not ETK, WZC) inhibitor | 0.431 0.005 DBMET00025 0.222 0.023 DBMET00026 0.447 0.005 DBMET00027 0.397 0.006 DBMET00028 0.305 0.011 DBMET03525 0.136 0.055 DBMET03527 0.364 0.007 DBMET03526 0.325 0.009 DBMET03528 0.318 0.01 DBMET03529 0.32 0.01 DBMET03530 0.338 0.009 DBMET03531 | ||
| 0.448 | 0.005 | 0.448 | Abl kinase inhibitor | 0.431 0.005 DBMET00025 0.221 0.023 DBMET00026 0.447 0.005 DBMET00027 0.396 0.006 DBMET00028 0.305 0.011 DBMET03525 0.136 0.055 DBMET03527 0.362 0.007 DBMET03526 0.325 0.009 DBMET03528 0.318 0.01 DBMET03529 0.319 0.01 DBMET03530 0.338 0.009 DBMET03531 | ||
| 0.437 | 0.005 | 0.437 | Protein-tyrosine kinase Lyn inhibitor | 0.431 0.005 DBMET00025 0.177 0.054 DBMET00026 0.33 0.014 DBMET00027 0.338 0.013 DBMET00028 0.289 0.021 DBMET03525 0.106 0.096 DBMET03527 0.407 0.006 DBMET03526 0.393 0.008 DBMET03528 0.377 0.009 DBMET03529 0.395 0.007 DBMET03530 0.39 0.008 DBMET03531 | ||
| 0.437 | 0.012 | 0.437 | EphB2 antagonist | 0.415 0.015 DBMET00025 0.191 0.094 DBMET00026 0.285 0.041 DBMET00027 0.302 0.035 DBMET00028 0.292 0.038 DBMET03525 0.16 0.119 DBMET03527 0.409 0.015 DBMET03526 0.369 0.021 DBMET03528 0.341 0.025 DBMET03529 0.366 0.021 DBMET03530 0.371 0.021 DBMET03531 | ||
| 0.407 | 0.011 | 0.407 | MAP kinase kinase 2 inhibitor | 0.39 0.013 DBMET00025 0.197 0.084 DBMET00026 0.22 0.069 DBMET00028 0.184 0.093 DBMET03525 0.344 0.022 DBMET03527 0.364 0.018 DBMET03526 0.318 0.029 DBMET03528 0.302 0.034 DBMET03529 0.306 0.033 DBMET03530 0.353 0.02 DBMET03531 | ||
| 0.404 | 0.016 | 0.44 | Death-associated protein kinase 3 inhibitor | 0.43 0.013 DBMET00025 0.292 0.04 DBMET00026 0.235 0.058 DBMET00027 0.266 0.047 DBMET00028 0.232 0.059 DBMET03525 0.44 0.012 DBMET03526 0.347 0.026 DBMET03528 0.374 0.021 DBMET03529 0.341 0.028 DBMET03530 0.409 0.016 DBMET03531 | DBMET03526 | |
| 0.392 | 0.005 | 0.404 | Growth factor agonist | 0.381 0.006 DBMET00025 0.207 0.056 DBMET00026 0.257 0.029 DBMET00027 0.33 0.01 DBMET00028 0.345 0.009 DBMET03525 0.164 0.113 DBMET03527 0.404 0.005 DBMET03526 0.368 0.007 DBMET03528 0.358 0.008 DBMET03529 0.377 0.006 DBMET03530 0.333 0.01 DBMET03531 | DBMET03526 | |
| 0.381 | 0.007 | 0.381 | Proto-oncogene tyrosine-protein kinase Kit inhibitor | 0.368 0.008 DBMET00025 0.089 0.064 DBMET00026 0.315 0.011 DBMET00027 0.257 0.015 DBMET00028 0.221 0.019 DBMET03525 0.091 0.062 DBMET03527 0.266 0.014 DBMET03526 0.293 0.012 DBMET03528 0.268 0.014 DBMET03529 0.276 0.014 DBMET03530 0.286 0.013 DBMET03531 | ||
| 0.371 | 0.009 | 0.374 | Aurora-B kinase inhibitor | 0.374 0.009 DBMET00025 0.164 0.041 DBMET00026 0.109 0.072 DBMET00027 0.222 0.026 DBMET00028 0.159 0.043 DBMET03525 0.104 0.077 DBMET03527 0.206 0.03 DBMET03526 0.227 0.025 DBMET03528 0.225 0.025 DBMET03529 0.261 0.019 DBMET03530 0.312 0.014 DBMET03531 | DBMET00025 | |
| 0.38 | 0.021 | 0.408 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.389 0.019 DBMET00025 0.245 0.058 DBMET00026 0.172 0.094 DBMET00027 0.226 0.064 DBMET00028 0.202 0.074 DBMET03525 0.201 0.074 DBMET03527 0.408 0.016 DBMET03526 0.331 0.034 DBMET03528 0.337 0.032 DBMET03529 0.325 0.036 DBMET03530 0.356 0.026 DBMET03531 | DBMET03526 | |
| 0.359 | 0.016 | 0.359 | Vascular endothelial growth factor antagonist | 0.322 0.019 DBMET00025 0.099 0.083 DBMET00026 0.197 0.039 DBMET00027 0.244 0.029 DBMET00028 0.138 0.059 DBMET03525 0.097 0.084 DBMET03527 0.262 0.027 DBMET03526 0.278 0.024 DBMET03528 0.242 0.03 DBMET03529 0.253 0.028 DBMET03530 0.272 0.025 DBMET03531 | ||
| 0.346 | 0.005 | 0.356 | I kappa B kinase epsilon inhibitor | 0.356 0.005 DBMET00025 0.304 0.013 DBMET00026 0.242 0.042 DBMET00027 0.243 0.041 DBMET00028 0.22 0.055 DBMET03525 0.287 0.02 DBMET03527 0.33 0.007 DBMET03526 0.29 0.019 DBMET03528 0.298 0.015 DBMET03529 0.292 0.018 DBMET03530 0.317 0.009 DBMET03531 | DBMET00025 | |
| 0.349 | 0.011 | 0.35 | Proto-oncogene tyrosine-protein kinase Yes inhibitor | 0.35 0.011 DBMET00025 0.15 0.061 DBMET00026 0.275 0.023 DBMET00027 0.278 0.022 DBMET00028 0.22 0.036 DBMET03525 0.191 0.044 DBMET03527 0.3 0.018 DBMET03526 0.287 0.02 DBMET03528 0.286 0.02 DBMET03529 0.279 0.022 DBMET03530 0.298 0.018 DBMET03531 | DBMET00025 | |
| 0.354 | 0.016 | 0.354 | Vascular endothelial growth factor 2 antagonist | 0.313 0.019 DBMET00025 0.085 0.083 DBMET00026 0.167 0.044 DBMET00027 0.231 0.029 DBMET00028 0.126 0.058 DBMET03525 0.244 0.027 DBMET03526 0.267 0.024 DBMET03528 0.222 0.03 DBMET03529 0.238 0.028 DBMET03530 0.258 0.025 DBMET03531 | ||
| 0.34 | 0.004 | 0.34 | Insulin receptor antagonist | 0.285 0.005 DBMET00025 0.134 0.034 DBMET00026 0.129 0.036 DBMET00027 0.228 0.01 DBMET00028 0.209 0.013 DBMET03525 0.131 0.035 DBMET03527 0.204 0.014 DBMET03526 0.273 0.005 DBMET03528 0.24 0.008 DBMET03529 0.255 0.007 DBMET03530 0.246 0.008 DBMET03531 | ||
| 0.36 | 0.024 | 0.472 | Platelet aggregation inhibitor | 0.369 0.023 DBMET00025 0.182 0.096 DBMET00026 0.322 0.031 DBMET00027 0.472 0.011 DBMET00028 0.254 0.05 DBMET03525 0.382 0.02 DBMET03526 0.354 0.025 DBMET03528 0.406 0.018 DBMET03529 0.356 0.025 DBMET03530 0.371 0.022 DBMET03531 | DBMET00028 | |
| 0.35 | 0.022 | 0.35 | Growth factor antagonist | 0.308 0.026 DBMET00025 0.119 0.093 DBMET00026 0.254 0.034 DBMET00027 0.208 0.044 DBMET00028 0.142 0.075 DBMET03525 0.147 0.071 DBMET03527 0.23 0.039 DBMET03526 0.329 0.024 DBMET03528 0.26 0.033 DBMET03529 0.276 0.031 DBMET03530 0.263 0.033 DBMET03531 | ||
| 0.337 | 0.009 | 0.337 | Platelet activating factor beta antagonist | 0.297 0.011 DBMET00025 0.084 0.076 DBMET00026 0.267 0.014 DBMET00027 0.229 0.019 DBMET00028 0.161 0.034 DBMET03525 0.09 0.07 DBMET03527 0.29 0.012 DBMET03526 0.247 0.017 DBMET03528 0.217 0.022 DBMET03529 0.228 0.019 DBMET03530 0.238 0.018 DBMET03531 | ||
| 0.333 | 0.006 | 0.39 | Polo-like kinase-3 inhibitor | 0.321 0.008 DBMET00025 0.225 0.033 DBMET00026 0.39 0.004 DBMET00027 0.271 0.018 DBMET00028 0.271 0.018 DBMET03525 0.27 0.018 DBMET03527 0.327 0.007 DBMET03526 0.319 0.008 DBMET03528 0.304 0.01 DBMET03529 0.298 0.012 DBMET03530 0.316 0.009 DBMET03531 | DBMET00027 | |
| 0.346 | 0.019 | 0.356 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.356 0.018 DBMET00025 0.332 0.023 DBMET00026 0.234 0.054 DBMET00027 0.208 0.063 DBMET00028 0.182 0.074 DBMET03525 0.348 0.019 DBMET03526 0.308 0.029 DBMET03528 0.316 0.026 DBMET03529 0.331 0.023 DBMET03530 0.328 0.023 DBMET03531 | DBMET00025 | |
| 0.34 | 0.013 | 0.34 | c-Src kinase inhibitor | 0.312 0.016 DBMET00025 0.147 0.057 DBMET00026 0.147 0.057 DBMET00027 0.284 0.02 DBMET00028 0.169 0.046 DBMET03525 0.177 0.043 DBMET03527 0.295 0.018 DBMET03526 0.292 0.019 DBMET03528 0.29 0.019 DBMET03529 0.24 0.027 DBMET03530 0.264 0.023 DBMET03531 | ||
| 0.329 | 0.005 | 0.329 | Stem cell growth factor agonist | 0.295 0.005 DBMET00025 0.093 0.051 DBMET00026 0.173 0.014 DBMET00027 0.248 0.006 DBMET00028 0.273 0.005 DBMET03525 0.254 0.005 DBMET03526 0.247 0.006 DBMET03528 0.223 0.008 DBMET03529 0.258 0.005 DBMET03530 0.24 0.006 DBMET03531 | ||
| 0.332 | 0.009 | 0.431 | Platelet activating factor antagonist | 0.305 0.011 DBMET00025 0.119 0.064 DBMET00026 0.238 0.018 DBMET00027 0.431 0.005 DBMET00028 0.224 0.021 DBMET03525 0.269 0.014 DBMET03526 0.262 0.015 DBMET03528 0.231 0.019 DBMET03529 0.241 0.018 DBMET03530 0.25 0.017 DBMET03531 | DBMET00028 | |
| 0.319 | 0.005 | 0.342 | Cyclin A inhibitor | 0.318 0.005 DBMET00025 0.116 0.018 DBMET00026 0.342 0.005 DBMET00028 0.094 0.025 DBMET03525 0.107 0.021 DBMET03527 0.135 0.015 DBMET03526 0.16 0.012 DBMET03528 0.187 0.01 DBMET03529 0.13 0.015 DBMET03530 0.157 0.012 DBMET03531 | DBMET00028 | |
| 0.321 | 0.009 | 0.34 | Cyclin-dependent kinase 7 inhibitor | 0.34 0.008 DBMET00025 0.271 0.017 DBMET00026 0.185 0.04 DBMET00027 0.281 0.015 DBMET00028 0.194 0.036 DBMET03525 0.202 0.033 DBMET03527 0.276 0.016 DBMET03526 0.265 0.018 DBMET03528 0.285 0.014 DBMET03529 0.263 0.018 DBMET03530 0.289 0.014 DBMET03531 | DBMET00025 | |
| 0.315 | 0.006 | 0.329 | Raf kinase inhibitor | 0.329 0.006 DBMET00025 0.107 0.029 DBMET00026 0.178 0.015 DBMET00027 0.167 0.016 DBMET00028 0.117 0.026 DBMET03525 0.298 0.007 DBMET03526 0.211 0.012 DBMET03528 0.227 0.01 DBMET03529 0.203 0.012 DBMET03530 0.244 0.009 DBMET03531 | DBMET00025 | |
| 0.316 | 0.008 | 0.331 | Protein kinase (Mos, Mil/Raf, MEKK, RIPK, TESK, LIMK, IRAK, ILK, Activin/TGF-beta) inhibitor | 0.331 0.007 DBMET00025 0.12 0.039 DBMET00026 0.187 0.02 DBMET00027 0.175 0.022 DBMET00028 0.132 0.034 DBMET03525 0.307 0.008 DBMET03526 0.221 0.015 DBMET03528 0.235 0.014 DBMET03529 0.213 0.016 DBMET03530 0.252 0.012 DBMET03531 | DBMET00025 | |
| 0.323 | 0.016 | 0.356 | Protein kinase (CK1) gamma 1 inhibitor | 0.322 0.016 DBMET00025 0.201 0.042 DBMET00026 0.197 0.044 DBMET00027 0.18 0.05 DBMET00028 0.162 0.06 DBMET03525 0.356 0.012 DBMET03526 0.29 0.021 DBMET03528 0.29 0.022 DBMET03529 0.254 0.028 DBMET03530 0.3 0.02 DBMET03531 | DBMET03526 | |
| 0.31 | 0.005 | 0.31 | Hedgehog signaling inhibitor | 0.309 0.005 DBMET00025 0.133 0.031 DBMET00026 0.129 0.033 DBMET00027 0.172 0.017 DBMET00028 0.153 0.023 DBMET03525 0.231 0.008 DBMET03526 0.277 0.005 DBMET03528 0.259 0.006 DBMET03529 0.257 0.006 DBMET03530 0.258 0.006 DBMET03531 | ||
| 0.311 | 0.007 | 0.317 | p38 MAP kinase inhibitor | 0.317 0.006 DBMET00025 0.107 0.03 DBMET00026 0.251 0.009 DBMET00028 0.245 0.01 DBMET03525 0.234 0.01 DBMET03526 0.262 0.009 DBMET03528 0.261 0.009 DBMET03529 0.271 0.008 DBMET03530 0.285 0.008 DBMET03531 | DBMET00025 | |
| 0.343 | 0.039 | 0.492 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.343 0.039 DBMET00025 0.317 0.052 DBMET00026 0.219 0.136 DBMET00027 0.255 0.101 DBMET00028 0.218 0.138 DBMET03525 0.492 0.008 DBMET03527 0.291 0.071 DBMET03526 0.309 0.058 DBMET03528 0.308 0.058 DBMET03529 0.302 0.062 DBMET03530 0.324 0.048 DBMET03531 | DBMET03527 | |
| 0.321 | 0.018 | 0.376 | Cyclin-dependent kinase inhibitor | 0.376 0.013 DBMET00025 0.214 0.034 DBMET00026 0.231 0.031 DBMET00028 0.119 0.074 DBMET03525 0.229 0.031 DBMET03527 0.272 0.024 DBMET03526 0.24 0.029 DBMET03528 0.291 0.021 DBMET03529 0.229 0.031 DBMET03530 0.302 0.02 DBMET03531 | DBMET00025 | |
| 0.316 | 0.014 | 0.344 | Protein kinase (CK1) gamma 3 inhibitor | 0.313 0.015 DBMET00025 0.229 0.033 DBMET00026 0.208 0.043 DBMET00027 0.203 0.045 DBMET00028 0.187 0.055 DBMET03525 0.344 0.011 DBMET03526 0.269 0.023 DBMET03528 0.264 0.024 DBMET03529 0.26 0.025 DBMET03530 0.292 0.018 DBMET03531 | DBMET03526 | |
| 0.322 | 0.021 | 0.378 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.344 0.016 DBMET00025 0.198 0.051 DBMET00026 0.231 0.041 DBMET00027 0.185 0.057 DBMET00028 0.166 0.067 DBMET03525 0.378 0.01 DBMET03526 0.32 0.021 DBMET03528 0.341 0.017 DBMET03529 0.289 0.028 DBMET03530 0.344 0.016 DBMET03531 | DBMET03526 | |
| 0.319 | 0.019 | 0.319 | RET inhibitor | 0.3 0.022 DBMET00025 0.135 0.069 DBMET00026 0.12 0.079 DBMET00027 0.156 0.058 DBMET00028 0.138 0.068 DBMET03525 0.152 0.06 DBMET03527 0.217 0.038 DBMET03526 0.298 0.023 DBMET03528 0.251 0.031 DBMET03529 0.265 0.029 DBMET03530 0.267 0.028 DBMET03531 | ||
| 0.32 | 0.021 | 0.346 | Protein kinase C nu inhibitor | 0.346 0.016 DBMET00025 0.222 0.04 DBMET00026 0.116 0.097 DBMET00027 0.155 0.067 DBMET00028 0.13 0.083 DBMET03525 0.137 0.077 DBMET03527 0.339 0.017 DBMET03526 0.281 0.028 DBMET03528 0.308 0.023 DBMET03529 0.238 0.037 DBMET03530 0.339 0.018 DBMET03531 | DBMET00025 | |
| 0.323 | 0.026 | 0.372 | CDC-like kinase 2 inhibitor | 0.337 0.023 DBMET00025 0.206 0.063 DBMET00026 0.187 0.074 DBMET00027 0.182 0.076 DBMET00028 0.177 0.079 DBMET03525 0.372 0.017 DBMET03526 0.256 0.043 DBMET03528 0.27 0.039 DBMET03529 0.245 0.047 DBMET03530 0.288 0.034 DBMET03531 | DBMET03526 | |
| 0.307 | 0.011 | 0.323 | Activin receptor-like kinase 2 inhibitor | 0.323 0.009 DBMET00025 0.168 0.054 DBMET00026 0.134 0.081 DBMET00028 0.129 0.086 DBMET03525 0.273 0.016 DBMET03527 0.148 0.068 DBMET03526 0.226 0.027 DBMET03528 0.243 0.022 DBMET03529 0.249 0.021 DBMET03530 0.259 0.019 DBMET03531 | DBMET00025 | |
| 0.297 | 0.004 | 0.297 | Fibroblast growth factor 3 antagonist | 0.262 0.004 DBMET00025 0.091 0.039 DBMET00026 0.103 0.031 DBMET00027 0.173 0.01 DBMET00028 0.137 0.017 DBMET03525 0.114 0.025 DBMET03527 0.129 0.02 DBMET03526 0.245 0.004 DBMET03528 0.17 0.01 DBMET03529 0.261 0.004 DBMET03530 0.291 0.004 DBMET03531 | ||
| 0.323 | 0.031 | 0.323 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.278 0.038 DBMET00025 0.206 0.061 DBMET00026 0.152 0.087 DBMET00028 0.134 0.101 DBMET03525 0.22 0.055 DBMET03527 0.254 0.044 DBMET03526 0.24 0.048 DBMET03528 0.209 0.06 DBMET03529 0.257 0.043 DBMET03530 0.253 0.044 DBMET03531 | ||
| 0.306 | 0.017 | 0.31 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.31 0.016 DBMET00025 0.21 0.043 DBMET00026 0.134 0.075 DBMET00027 0.181 0.052 DBMET00028 0.123 0.082 DBMET03525 0.195 0.047 DBMET03527 0.308 0.017 DBMET03526 0.279 0.023 DBMET03528 0.282 0.023 DBMET03529 0.252 0.031 DBMET03530 0.28 0.023 DBMET03531 | DBMET00025 | |
| 0.307 | 0.019 | 0.343 | LIM domain kinase 1 inhibitor | 0.302 0.021 DBMET00025 0.132 0.118 DBMET00028 0.138 0.111 DBMET03525 0.171 0.079 DBMET03527 0.343 0.013 DBMET03526 0.231 0.048 DBMET03528 0.227 0.05 DBMET03529 0.214 0.057 DBMET03530 0.248 0.039 DBMET03531 | DBMET03526 | |
| 0.279 | 0.005 | 0.305 | MAP kinase 3 inhibitor | 0.276 0.005 DBMET00025 0.216 0.017 DBMET00026 0.154 0.062 DBMET00027 0.178 0.036 DBMET00028 0.156 0.059 DBMET03525 0.14 0.085 DBMET03527 0.305 0.004 DBMET03526 0.272 0.005 DBMET03528 0.269 0.006 DBMET03529 0.241 0.01 DBMET03530 0.244 0.009 DBMET03531 | DBMET03526 | |
| 0.276 | 0.004 | 0.334 | Polo-like kinase-1 inhibitor | 0.212 0.005 DBMET00025 0.154 0.015 DBMET00026 0.243 0.004 DBMET00027 0.227 0.005 DBMET00028 0.171 0.011 DBMET03525 0.159 0.014 DBMET03527 0.212 0.005 DBMET03526 0.334 0.003 DBMET03528 0.21 0.005 DBMET03529 0.3 0.004 DBMET03530 0.242 0.004 DBMET03531 | DBMET03528 | |
| 0.287 | 0.02 | 0.357 | Tumour necrosis factor antagonist | 0.357 0.01 DBMET00025 0.156 0.094 DBMET00026 0.317 0.015 DBMET00028 0.212 0.046 DBMET03525 0.23 0.038 DBMET03527 0.233 0.036 DBMET03526 0.257 0.029 DBMET03528 0.324 0.014 DBMET03529 0.174 0.073 DBMET03530 0.281 0.022 DBMET03531 | DBMET00025 | |
| 0.279 | 0.015 | 0.279 | Aurora-A kinase inhibitor | 0.275 0.015 DBMET00025 0.131 0.049 DBMET00026 0.097 0.069 DBMET00027 0.182 0.03 DBMET00028 0.13 0.049 DBMET03525 0.1 0.066 DBMET03527 0.22 0.022 DBMET03526 0.212 0.023 DBMET03528 0.207 0.024 DBMET03529 0.198 0.026 DBMET03530 0.215 0.023 DBMET03531 | ||
| 0.302 | 0.038 | 0.302 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.291 0.042 DBMET00025 0.155 0.137 DBMET00026 0.161 0.13 DBMET00027 0.171 0.118 DBMET00028 0.19 0.099 DBMET03525 0.264 0.053 DBMET03526 0.247 0.062 DBMET03528 0.234 0.069 DBMET03529 0.243 0.064 DBMET03530 0.273 0.05 DBMET03531 | ||
| 0.359 | 0.096 | 0.645 | Histamine release inhibitor | 0.255 0.152 DBMET00025 0.394 0.079 DBMET03527 0.645 0.007 DBMET03526 0.235 0.167 DBMET03528 0.209 0.191 DBMET03530 0.242 0.161 DBMET03531 | DBMET03526 | |
| 0.284 | 0.021 | 0.307 | Focal adhesion kinase 2 inhibitor | 0.29 0.019 DBMET00025 0.15 0.131 DBMET00028 0.236 0.045 DBMET03527 0.307 0.014 DBMET03526 0.242 0.042 DBMET03528 0.249 0.038 DBMET03529 0.239 0.043 DBMET03530 0.258 0.033 DBMET03531 | DBMET03526 | |
| 0.268 | 0.006 | 0.292 | Raf kinase B inhibitor | 0.292 0.005 DBMET00025 0.091 0.025 DBMET00026 0.134 0.016 DBMET00027 0.134 0.016 DBMET00028 0.09 0.025 DBMET03525 0.272 0.006 DBMET03526 0.177 0.011 DBMET03528 0.203 0.009 DBMET03529 0.166 0.012 DBMET03530 0.208 0.009 DBMET03531 | DBMET00025 | |
| 0.311 | 0.049 | 0.437 | Dyrk kinase inhibitor | 0.307 0.05 DBMET00025 0.181 0.109 DBMET00026 0.168 0.12 DBMET00028 0.168 0.119 DBMET03525 0.437 0.021 DBMET03526 0.241 0.076 DBMET03528 0.237 0.078 DBMET03529 0.232 0.08 DBMET03530 0.258 0.068 DBMET03531 | DBMET03526 | |
| 0.279 | 0.02 | 0.279 | Tyrosine-protein kinase receptor antagonist | 0.272 0.022 DBMET00025 0.177 0.05 DBMET00026 0.122 0.085 DBMET03525 0.139 0.071 DBMET03527 0.132 0.076 DBMET03526 0.23 0.031 DBMET03528 0.191 0.044 DBMET03529 0.244 0.028 DBMET03530 0.274 0.022 DBMET03531 | ||
| 0.28 | 0.022 | 0.322 | Protein kinase (CK1) gamma inhibitor | 0.286 0.021 DBMET00025 0.157 0.063 DBMET00026 0.216 0.039 DBMET00027 0.151 0.066 DBMET00028 0.129 0.082 DBMET03525 0.322 0.014 DBMET03526 0.252 0.029 DBMET03528 0.257 0.028 DBMET03529 0.222 0.037 DBMET03530 0.282 0.022 DBMET03531 | DBMET03526 | |
| 0.262 | 0.005 | 0.262 | Platelet growth factor antagonist | 0.239 0.006 DBMET00025 0.09 0.048 DBMET00026 0.251 0.005 DBMET00027 0.153 0.018 DBMET00028 0.142 0.022 DBMET03525 0.111 0.034 DBMET03527 0.25 0.005 DBMET03526 0.214 0.008 DBMET03528 0.2 0.009 DBMET03529 0.201 0.009 DBMET03530 0.204 0.009 DBMET03531 | ||
| 0.263 | 0.01 | 0.263 | Platelet activating factor alpha antagonist | 0.247 0.011 DBMET00025 0.11 0.052 DBMET00026 0.117 0.046 DBMET00027 0.168 0.024 DBMET00028 0.144 0.033 DBMET03525 0.23 0.013 DBMET03526 0.206 0.015 DBMET03528 0.186 0.019 DBMET03529 0.2 0.016 DBMET03530 0.214 0.014 DBMET03531 | ||
| 0.264 | 0.013 | 0.35 | Cyclin-dependent kinase 9 inhibitor | 0.292 0.01 DBMET00025 0.11 0.053 DBMET00026 0.086 0.081 DBMET00027 0.35 0.006 DBMET00028 0.139 0.037 DBMET03525 0.123 0.044 DBMET03527 0.214 0.02 DBMET03526 0.162 0.031 DBMET03528 0.188 0.025 DBMET03529 0.159 0.031 DBMET03530 0.195 0.024 DBMET03531 | DBMET00028 | |
| 0.266 | 0.017 | 0.268 | TRKA antagonist | 0.259 0.018 DBMET00025 0.157 0.046 DBMET00026 0.131 0.06 DBMET03527 0.126 0.063 DBMET03526 0.212 0.027 DBMET03528 0.171 0.039 DBMET03529 0.187 0.034 DBMET03530 0.268 0.016 DBMET03531 | DBMET03531 | |
| 0.262 | 0.013 | 0.262 | Cyclin-dependent kinase 8 inhibitor | 0.262 0.013 DBMET00025 0.199 0.036 DBMET00026 0.172 0.059 DBMET00028 0.161 0.069 DBMET03525 0.207 0.031 DBMET03527 0.172 0.059 DBMET03526 0.21 0.029 DBMET03528 0.233 0.02 DBMET03529 0.216 0.026 DBMET03530 0.243 0.018 DBMET03531 | ||
| 0.255 | 0.007 | 0.28 | Cyclin A2 inhibitor | 0.252 0.007 DBMET00025 0.099 0.025 DBMET00026 0.28 0.006 DBMET00028 0.077 0.034 DBMET03525 0.116 0.02 DBMET03527 0.138 0.015 DBMET03526 0.136 0.015 DBMET03528 0.155 0.013 DBMET03529 0.109 0.022 DBMET03530 0.126 0.017 DBMET03531 | DBMET00028 | |
| 0.281 | 0.034 | 0.281 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.275 0.036 DBMET00025 0.184 0.089 DBMET00026 0.198 0.075 DBMET00028 0.161 0.117 DBMET03525 0.227 0.053 DBMET03527 0.228 0.053 DBMET03526 0.234 0.05 DBMET03528 0.229 0.052 DBMET03529 0.224 0.055 DBMET03530 0.233 0.05 DBMET03531 | ||
| 0.249 | 0.006 | 0.249 | Insulin growth factor antagonist | 0.227 0.008 DBMET00025 0.094 0.05 DBMET00026 0.084 0.061 DBMET00027 0.13 0.029 DBMET00028 0.088 0.057 DBMET03525 0.115 0.037 DBMET03527 0.144 0.024 DBMET03526 0.191 0.012 DBMET03528 0.174 0.016 DBMET03529 0.174 0.016 DBMET03530 0.173 0.016 DBMET03531 | ||
| 0.264 | 0.023 | 0.315 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.277 0.02 DBMET00025 0.169 0.06 DBMET00026 0.161 0.065 DBMET00027 0.199 0.042 DBMET00028 0.144 0.079 DBMET03525 0.315 0.013 DBMET03526 0.213 0.036 DBMET03528 0.222 0.033 DBMET03529 0.214 0.036 DBMET03530 0.232 0.03 DBMET03531 | DBMET03526 | |
| 0.278 | 0.037 | 0.278 | TRKC antagonist | 0.261 0.043 DBMET00025 0.168 0.087 DBMET00026 0.131 0.119 DBMET00027 0.167 0.088 DBMET00028 0.218 0.06 DBMET03525 0.202 0.067 DBMET03527 0.19 0.073 DBMET03526 0.263 0.043 DBMET03528 0.227 0.056 DBMET03529 0.272 0.039 DBMET03530 0.245 0.05 DBMET03531 | ||
| 0.245 | 0.005 | 0.245 | Insulin like growth factor 1 antagonist | 0.223 0.007 DBMET00025 0.09 0.049 DBMET00026 0.082 0.058 DBMET00027 0.125 0.028 DBMET00028 0.085 0.054 DBMET03525 0.108 0.036 DBMET03527 0.118 0.03 DBMET03526 0.187 0.012 DBMET03528 0.169 0.015 DBMET03529 0.17 0.015 DBMET03530 0.168 0.015 DBMET03531 | ||
| 0.281 | 0.041 | 0.281 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.254 0.049 DBMET00025 0.211 0.069 DBMET00026 0.154 0.122 DBMET00027 0.159 0.117 DBMET00028 0.151 0.126 DBMET03525 0.243 0.053 DBMET03527 0.235 0.057 DBMET03526 0.222 0.063 DBMET03528 0.202 0.075 DBMET03529 0.21 0.07 DBMET03530 0.272 0.044 DBMET03531 | ||
| 0.251 | 0.014 | 0.286 | CDK/cyclin complex inhibitor | 0.286 0.011 DBMET00025 0.174 0.024 DBMET00026 0.165 0.026 DBMET00028 0.088 0.061 DBMET03525 0.139 0.033 DBMET03527 0.209 0.018 DBMET03526 0.197 0.02 DBMET03528 0.221 0.016 DBMET03529 0.191 0.02 DBMET03530 0.251 0.014 DBMET03531 | DBMET00025 | |
| 0.281 | 0.044 | 0.316 | Clk dual-specificity kinase inhibitor | 0.286 0.042 DBMET00025 0.152 0.112 DBMET00026 0.143 0.121 DBMET00027 0.178 0.093 DBMET00028 0.156 0.108 DBMET03525 0.316 0.035 DBMET03526 0.23 0.063 DBMET03528 0.234 0.062 DBMET03529 0.228 0.064 DBMET03530 0.248 0.056 DBMET03531 | DBMET03526 | |
| 0.241 | 0.005 | 0.241 | Macrophage colony-stimulating factor 1 receptor antagonist | 0.224 0.007 DBMET00025 0.077 0.044 DBMET00026 0.221 0.007 DBMET00027 0.225 0.006 DBMET00028 0.141 0.016 DBMET03525 0.142 0.016 DBMET03527 0.133 0.018 DBMET03526 0.204 0.008 DBMET03528 0.179 0.01 DBMET03529 0.181 0.01 DBMET03530 0.177 0.01 DBMET03531 | ||
| 0.285 | 0.054 | 0.425 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.279 0.056 DBMET00025 0.174 0.11 DBMET00026 0.15 0.131 DBMET03525 0.425 0.022 DBMET03526 0.206 0.089 DBMET03528 0.201 0.092 DBMET03529 0.211 0.086 DBMET03530 0.233 0.075 DBMET03531 | DBMET03526 | |
| 0.251 | 0.022 | 0.261 | Glycogen synthase kinase-3 inhibitor | 0.25 0.022 DBMET00025 0.122 0.06 DBMET00026 0.093 0.086 DBMET00027 0.158 0.043 DBMET00028 0.098 0.081 DBMET03525 0.229 0.025 DBMET03526 0.212 0.029 DBMET03528 0.192 0.033 DBMET03529 0.218 0.027 DBMET03530 0.261 0.02 DBMET03531 | DBMET03531 | |
| 0.265 | 0.039 | 0.354 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.297 0.028 DBMET00025 0.164 0.107 DBMET00026 0.203 0.074 DBMET00027 0.166 0.105 DBMET00028 0.201 0.075 DBMET03525 0.354 0.017 DBMET03526 0.243 0.049 DBMET03528 0.272 0.036 DBMET03529 0.224 0.06 DBMET03530 0.272 0.036 DBMET03531 | DBMET03526 | |
| 0.252 | 0.026 | 0.428 | Tyrosine-protein kinase receptor FLT3 inhibitor | 0.245 0.027 DBMET00025 0.127 0.064 DBMET00026 0.253 0.026 DBMET00027 0.126 0.064 DBMET00028 0.428 0.009 DBMET03527 0.096 0.082 DBMET03526 0.167 0.046 DBMET03528 0.151 0.053 DBMET03529 0.155 0.051 DBMET03530 0.179 0.042 DBMET03531 | DBMET03527 | |
| 0.243 | 0.018 | 0.243 | Cyclin-dependent kinase 3 inhibitor | 0.233 0.02 DBMET00025 0.218 0.025 DBMET00026 0.174 0.056 DBMET00027 0.209 0.028 DBMET00028 0.171 0.059 DBMET03525 0.155 0.085 DBMET03527 0.228 0.021 DBMET03526 0.224 0.023 DBMET03528 0.215 0.026 DBMET03529 0.224 0.023 DBMET03530 0.234 0.02 DBMET03531 | ||
| 0.268 | 0.046 | 0.309 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.28 0.037 DBMET00025 0.248 0.068 DBMET00026 0.218 0.119 DBMET00027 0.225 0.105 DBMET00028 0.218 0.12 DBMET03525 0.309 0.021 DBMET03527 0.214 0.128 DBMET03526 0.245 0.072 DBMET03528 0.256 0.058 DBMET03529 0.25 0.066 DBMET03530 0.27 0.044 DBMET03531 | DBMET03527 | |
| 0.235 | 0.017 | 0.266 | MAP kinase 9 inhibitor | 0.259 0.015 DBMET00025 0.163 0.033 DBMET00026 0.083 0.079 DBMET00027 0.135 0.043 DBMET00028 0.139 0.042 DBMET03525 0.266 0.015 DBMET03526 0.174 0.029 DBMET03528 0.175 0.029 DBMET03529 0.169 0.031 DBMET03530 0.212 0.02 DBMET03531 | DBMET03526 | |
| 0.248 | 0.033 | 0.255 | MAP kinase kinase 3 inhibitor | 0.252 0.029 DBMET00025 0.225 0.064 DBMET00026 0.244 0.038 DBMET00027 0.209 0.097 DBMET00028 0.225 0.064 DBMET03525 0.228 0.06 DBMET03526 0.229 0.057 DBMET03528 0.234 0.051 DBMET03529 0.238 0.044 DBMET03530 0.255 0.027 DBMET03531 | DBMET03531 | |
| 0.236 | 0.022 | 0.244 | Glycogen synthase kinase-3 beta inhibitor | 0.238 0.022 DBMET00025 0.125 0.058 DBMET00026 0.15 0.043 DBMET00028 0.097 0.082 DBMET03525 0.211 0.026 DBMET03526 0.193 0.03 DBMET03528 0.182 0.033 DBMET03529 0.196 0.03 DBMET03530 0.244 0.021 DBMET03531 | DBMET03531 | |
| 0.222 | 0.01 | 0.263 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.217 0.012 DBMET00025 0.176 0.036 DBMET00026 0.158 0.058 DBMET00027 0.187 0.027 DBMET00028 0.173 0.039 DBMET03525 0.16 0.056 DBMET03527 0.263 0.005 DBMET03526 0.201 0.018 DBMET03528 0.196 0.021 DBMET03529 0.199 0.019 DBMET03530 0.206 0.016 DBMET03531 | DBMET03526 | |
| 0.234 | 0.024 | 0.277 | Protein kinase (CK1) gamma 2 inhibitor | 0.246 0.021 DBMET00025 0.126 0.061 DBMET00026 0.183 0.037 DBMET00027 0.118 0.067 DBMET00028 0.101 0.083 DBMET03525 0.277 0.015 DBMET03526 0.185 0.036 DBMET03528 0.196 0.033 DBMET03529 0.18 0.038 DBMET03530 0.244 0.022 DBMET03531 | DBMET03526 | |
| 0.218 | 0.012 | 0.232 | CDK2/cyclin A inhibitor | 0.232 0.01 DBMET00025 0.153 0.025 DBMET00026 0.092 0.066 DBMET00027 0.183 0.017 DBMET00028 0.118 0.044 DBMET03525 0.111 0.049 DBMET03527 0.21 0.013 DBMET03526 0.181 0.017 DBMET03528 0.191 0.015 DBMET03529 0.178 0.018 DBMET03530 0.191 0.015 DBMET03531 | DBMET00025 | |
| 0.221 | 0.023 | 0.246 | Cyclin-dependent kinase 1 inhibitor | 0.246 0.018 DBMET00025 0.15 0.041 DBMET00026 0.139 0.046 DBMET00028 0.142 0.044 DBMET03527 0.195 0.027 DBMET03526 0.156 0.039 DBMET03528 0.177 0.031 DBMET03529 0.146 0.043 DBMET03530 0.188 0.029 DBMET03531 | DBMET00025 | |
| 0.21 | 0.015 | 0.254 | MAP kinase 8 inhibitor | 0.22 0.013 DBMET00025 0.174 0.022 DBMET00026 0.098 0.062 DBMET00027 0.143 0.032 DBMET00028 0.175 0.021 DBMET03525 0.254 0.01 DBMET03526 0.163 0.025 DBMET03528 0.163 0.025 DBMET03529 0.16 0.026 DBMET03530 0.178 0.021 DBMET03531 | DBMET03526 | |
| 0.201 | 0.006 | 0.225 | CDK9/cyclin T1 inhibitor | 0.225 0.006 DBMET00025 0.103 0.018 DBMET00026 0.074 0.029 DBMET00027 0.195 0.007 DBMET00028 0.073 0.03 DBMET03525 0.179 0.008 DBMET03526 0.151 0.01 DBMET03528 0.163 0.009 DBMET03529 0.143 0.011 DBMET03530 0.166 0.009 DBMET03531 | DBMET00025 | |
| 0.216 | 0.022 | 0.243 | Cyclin-dependent kinase 2 inhibitor | 0.243 0.018 DBMET00025 0.149 0.038 DBMET00026 0.178 0.029 DBMET00028 0.095 0.076 DBMET03525 0.114 0.057 DBMET03527 0.203 0.024 DBMET03526 0.161 0.033 DBMET03528 0.19 0.026 DBMET03529 0.152 0.037 DBMET03530 0.209 0.023 DBMET03531 | DBMET00025 | |
| 0.204 | 0.011 | 0.347 | ALK inhibitor | 0.211 0.01 DBMET00025 0.081 0.058 DBMET00026 0.125 0.027 DBMET00028 0.115 0.032 DBMET03525 0.347 0.005 DBMET03527 0.112 0.034 DBMET03526 0.184 0.014 DBMET03528 0.203 0.011 DBMET03529 0.195 0.012 DBMET03530 0.179 0.014 DBMET03531 | DBMET03527 | |
| 0.216 | 0.023 | 0.223 | Vascular endothelial growth factor 1 antagonist | 0.188 0.029 DBMET00025 0.088 0.075 DBMET00026 0.223 0.022 DBMET00027 0.125 0.052 DBMET00028 0.092 0.071 DBMET03525 0.164 0.036 DBMET03526 0.154 0.039 DBMET03528 0.13 0.049 DBMET03529 0.133 0.048 DBMET03530 0.14 0.045 DBMET03531 | DBMET00027 | |
| 0.201 | 0.011 | 0.244 | MAP kinase 14 inhibitor | 0.204 0.011 DBMET00025 0.244 0.008 DBMET00028 0.141 0.021 DBMET03525 0.186 0.013 DBMET03526 0.158 0.017 DBMET03528 0.148 0.019 DBMET03529 0.146 0.02 DBMET03530 0.163 0.017 DBMET03531 | DBMET00028 | |
| 0.238 | 0.05 | 0.278 | CDC-like kinase 4 inhibitor | 0.258 0.043 DBMET00025 0.129 0.119 DBMET00026 0.156 0.096 DBMET00028 0.143 0.107 DBMET03525 0.278 0.037 DBMET03526 0.185 0.075 DBMET03528 0.202 0.066 DBMET03529 0.186 0.075 DBMET03530 0.224 0.056 DBMET03531 | DBMET03526 | |
| 0.221 | 0.035 | 0.32 | Glycogen synthase kinase-3 alpha inhibitor | 0.254 0.025 DBMET00025 0.104 0.1 DBMET00026 0.121 0.084 DBMET03527 0.32 0.014 DBMET03526 0.187 0.045 DBMET03528 0.208 0.039 DBMET03529 0.137 0.074 DBMET03530 0.243 0.028 DBMET03531 | DBMET03526 | |
| 0.212 | 0.027 | 0.226 | Death-associated protein kinase 2 inhibitor | 0.226 0.02 DBMET00025 0.162 0.082 DBMET00026 0.18 0.054 DBMET00027 0.192 0.041 DBMET00028 0.192 0.041 DBMET03525 0.15 0.106 DBMET03527 0.188 0.045 DBMET03526 0.191 0.042 DBMET03528 0.204 0.031 DBMET03529 0.201 0.034 DBMET03530 0.218 0.024 DBMET03531 | DBMET00025 | |
| 0.199 | 0.014 | 0.243 | Protein kinase C gamma inhibitor | 0.18 0.019 DBMET00025 0.207 0.013 DBMET00026 0.1 0.076 DBMET00028 0.133 0.043 DBMET03525 0.243 0.008 DBMET03527 0.225 0.01 DBMET03526 0.168 0.023 DBMET03528 0.152 0.03 DBMET03529 0.137 0.04 DBMET03530 0.158 0.027 DBMET03531 | DBMET03527 | |
| 0.264 | 0.08 | 0.264 | Ca(v)3.3 blocker | 0.246 0.107 DBMET00025 0.231 0.132 DBMET00026 0.206 0.179 DBMET00027 0.22 0.152 DBMET00028 0.224 0.144 DBMET03525 0.209 0.172 DBMET03527 0.224 0.144 DBMET03528 0.2 0.192 DBMET03529 0.241 0.115 DBMET03530 0.22 0.152 DBMET03531 | ||
| 0.191 | 0.009 | 0.287 | Rho-associated kinase I inhibitor | 0.287 0.005 DBMET00025 0.097 0.033 DBMET00026 0.129 0.019 DBMET00028 0.066 0.061 DBMET03525 0.078 0.048 DBMET03527 0.089 0.039 DBMET03526 0.095 0.034 DBMET03528 0.14 0.016 DBMET03529 0.097 0.033 DBMET03530 0.163 0.013 DBMET03531 | DBMET00025 | |
| 0.196 | 0.016 | 0.196 | TIE antagonist | 0.166 0.02 DBMET00025 0.148 0.023 DBMET00027 0.132 0.027 DBMET00028 0.097 0.044 DBMET03525 0.142 0.025 DBMET03526 0.127 0.028 DBMET03528 0.108 0.036 DBMET03529 0.12 0.031 DBMET03530 0.144 0.024 DBMET03531 | ||
| 0.205 | 0.027 | 0.265 | MAP kinase kinase inhibitor | 0.179 0.037 DBMET00025 0.177 0.038 DBMET00026 0.106 0.088 DBMET00028 0.149 0.052 DBMET03527 0.265 0.013 DBMET03526 0.159 0.047 DBMET03528 0.12 0.074 DBMET03529 0.139 0.058 DBMET03530 0.176 0.038 DBMET03531 | DBMET03526 | |
| 0.196 | 0.021 | 0.202 | Aurora-C kinase inhibitor | 0.202 0.019 DBMET00025 0.144 0.059 DBMET00026 0.133 0.076 DBMET00027 0.16 0.04 DBMET00028 0.143 0.06 DBMET03525 0.16 0.04 DBMET03527 0.198 0.02 DBMET03526 0.172 0.031 DBMET03528 0.177 0.028 DBMET03529 0.167 0.034 DBMET03530 0.178 0.028 DBMET03531 | DBMET00025 | |
| 0.186 | 0.013 | 0.201 | Rho-associated kinase II inhibitor | 0.201 0.011 DBMET00025 0.112 0.027 DBMET00026 0.092 0.037 DBMET00027 0.107 0.029 DBMET00028 0.097 0.033 DBMET03525 0.123 0.024 DBMET03526 0.121 0.024 DBMET03528 0.13 0.022 DBMET03529 0.116 0.026 DBMET03530 0.141 0.019 DBMET03531 | DBMET00025 | |
| 0.189 | 0.018 | 0.307 | Polo-like kinase-4 inhibitor | 0.173 0.024 DBMET00025 0.14 0.042 DBMET00026 0.102 0.075 DBMET00027 0.165 0.028 DBMET00028 0.161 0.029 DBMET03525 0.307 0.005 DBMET03527 0.133 0.047 DBMET03526 0.188 0.019 DBMET03528 0.164 0.028 DBMET03529 0.236 0.009 DBMET03530 0.234 0.01 DBMET03531 | DBMET03527 | |
| 0.185 | 0.016 | 0.185 | TIE-2 antagonist | 0.156 0.021 DBMET00025 0.139 0.024 DBMET00027 0.126 0.028 DBMET00028 0.092 0.045 DBMET03525 0.134 0.026 DBMET03526 0.121 0.029 DBMET03528 0.103 0.038 DBMET03529 0.115 0.032 DBMET03530 0.135 0.025 DBMET03531 | ||
| 0.194 | 0.026 | 0.233 | Ephrin antagonist | 0.179 0.03 DBMET00025 0.233 0.017 DBMET00027 0.119 0.051 DBMET00028 0.087 0.076 DBMET03525 0.147 0.038 DBMET03526 0.16 0.034 DBMET03528 0.156 0.035 DBMET03529 0.148 0.037 DBMET03530 0.178 0.03 DBMET03531 | DBMET00027 | |
| 0.204 | 0.035 | 0.251 | Ribosomal protein S6 kinase inhibitor | 0.217 0.031 DBMET00025 0.115 0.096 DBMET00026 0.143 0.07 DBMET00027 0.144 0.069 DBMET00028 0.141 0.072 DBMET03525 0.138 0.074 DBMET03527 0.172 0.051 DBMET03526 0.193 0.04 DBMET03528 0.19 0.041 DBMET03529 0.185 0.044 DBMET03530 0.251 0.02 DBMET03531 | DBMET03531 | |
| 0.236 | 0.069 | 0.315 | MAP-kinase-activated kinase 5 inhibitor | 0.246 0.062 DBMET00025 0.229 0.074 DBMET00026 0.315 0.022 DBMET03527 0.194 0.11 DBMET03526 0.225 0.078 DBMET03528 0.261 0.052 DBMET03529 0.201 0.102 DBMET03530 0.265 0.05 DBMET03531 | DBMET03527 | |
| 0.204 | 0.038 | 0.218 | Protein kinase (CK1) inhibitor | 0.218 0.035 DBMET00025 0.13 0.083 DBMET00026 0.114 0.097 DBMET00027 0.146 0.071 DBMET03527 0.201 0.039 DBMET03526 0.161 0.059 DBMET03528 0.168 0.054 DBMET03529 0.154 0.064 DBMET03530 0.176 0.05 DBMET03531 | DBMET00025 | |
| 0.191 | 0.026 | 0.573 | Protein kinase (CK2) alpha inhibitor | 0.199 0.024 DBMET00025 0.573 0.003 DBMET03526 0.135 0.052 DBMET03528 0.139 0.049 DBMET03529 0.107 0.071 DBMET03530 0.145 0.044 DBMET03531 | DBMET03526 | |
| 0.172 | 0.009 | 0.172 | EphB4 antagonist | 0.119 0.014 DBMET00025 0.139 0.011 DBMET00027 0.068 0.031 DBMET00028 0.054 0.045 DBMET03527 0.062 0.036 DBMET03526 0.119 0.014 DBMET03528 0.07 0.03 DBMET03529 0.108 0.016 DBMET03530 0.082 0.023 DBMET03531 | ||
| 0.166 | 0.004 | 0.18 | Cyclin-dependent kinase 6 inhibitor | 0.18 0.004 DBMET00025 0.124 0.006 DBMET00026 0.101 0.01 DBMET00028 0.103 0.009 DBMET03525 0.15 0.004 DBMET03527 0.069 0.032 DBMET03526 0.147 0.004 DBMET03528 0.162 0.004 DBMET03529 0.133 0.005 DBMET03530 0.158 0.004 DBMET03531 | DBMET00025 | |
| 0.173 | 0.012 | 0.191 | CDK1/cyclin B1 inhibitor | 0.191 0.009 DBMET00025 0.14 0.018 DBMET00026 0.142 0.017 DBMET00028 0.073 0.044 DBMET03525 0.144 0.017 DBMET03527 0.15 0.016 DBMET03526 0.137 0.018 DBMET03528 0.157 0.014 DBMET03529 0.129 0.02 DBMET03530 0.154 0.015 DBMET03531 | DBMET00025 | |
| 0.172 | 0.011 | 0.216 | Syk tyrosine kinase inhibitor | 0.15 0.014 DBMET00025 0.142 0.015 DBMET00026 0.08 0.04 DBMET00028 0.081 0.04 DBMET03527 0.216 0.007 DBMET03526 0.128 0.019 DBMET03528 0.098 0.029 DBMET03529 0.12 0.02 DBMET03530 0.145 0.015 DBMET03531 | DBMET03526 | |
| 0.174 | 0.016 | 0.192 | Death-associated protein kinase 1 inhibitor | 0.192 0.009 DBMET00025 0.151 0.037 DBMET00026 0.144 0.05 DBMET00027 0.147 0.044 DBMET00028 0.157 0.03 DBMET03525 0.131 0.078 DBMET03527 0.164 0.023 DBMET03526 0.16 0.027 DBMET03528 0.176 0.015 DBMET03529 0.165 0.023 DBMET03530 0.181 0.013 DBMET03531 | DBMET00025 | |
| 0.17 | 0.013 | 0.17 | MAP kinase 10 inhibitor | 0.165 0.014 DBMET00025 0.111 0.029 DBMET00026 0.085 0.046 DBMET00027 0.1 0.035 DBMET00028 0.1 0.035 DBMET03525 0.15 0.016 DBMET03526 0.128 0.021 DBMET03528 0.119 0.024 DBMET03529 0.122 0.023 DBMET03530 0.126 0.022 DBMET03531 | ||
| 0.165 | 0.01 | 0.165 | Proto-oncogene tyrosine-protein kinase c-hck inhibitor | 0.158 0.011 DBMET00025 0.103 0.034 DBMET00027 0.136 0.018 DBMET00028 0.125 0.023 DBMET03525 0.156 0.012 DBMET03526 0.147 0.014 DBMET03528 0.14 0.017 DBMET03529 0.141 0.017 DBMET03530 0.141 0.016 DBMET03531 | ||
| 0.166 | 0.017 | 0.166 | ErbB-4 antagonist | 0.13 0.027 DBMET00025 0.072 0.058 DBMET00026 0.113 0.034 DBMET00028 0.085 0.049 DBMET03525 0.113 0.034 DBMET03527 0.1 0.04 DBMET03526 0.153 0.02 DBMET03528 0.111 0.035 DBMET03529 0.144 0.022 DBMET03530 0.112 0.034 DBMET03531 | ||
| 0.155 | 0.009 | 0.19 | MAP kinase kinase 10 inhibitor | 0.158 0.009 DBMET00025 0.126 0.014 DBMET00026 0.067 0.044 DBMET00027 0.085 0.025 DBMET00028 0.068 0.043 DBMET03525 0.19 0.006 DBMET03526 0.122 0.014 DBMET03528 0.124 0.014 DBMET03529 0.12 0.015 DBMET03530 0.12 0.015 DBMET03531 | DBMET03526 | |
| 0.155 | 0.011 | 0.248 | Cyclin-dependent kinase 4 inhibitor | 0.191 0.008 DBMET00025 0.127 0.016 DBMET00026 0.096 0.028 DBMET00028 0.064 0.047 DBMET03525 0.248 0.005 DBMET03527 0.11 0.022 DBMET03526 0.13 0.016 DBMET03528 0.16 0.01 DBMET03529 0.122 0.018 DBMET03530 0.161 0.01 DBMET03531 | DBMET03527 | |
| 0.152 | 0.009 | 0.217 | CDC7 inhibitor | 0.2 0.005 DBMET00025 0.081 0.035 DBMET00026 0.071 0.043 DBMET03527 0.137 0.012 DBMET03526 0.129 0.013 DBMET03528 0.153 0.009 DBMET03529 0.113 0.018 DBMET03530 0.217 0.005 DBMET03531 | DBMET03531 | |
| 0.156 | 0.016 | 0.182 | Interleukin 2 antagonist | 0.142 0.023 DBMET00025 0.115 0.054 DBMET00026 0.109 0.066 DBMET00027 0.112 0.058 DBMET00028 0.124 0.039 DBMET03525 0.125 0.039 DBMET03527 0.146 0.02 DBMET03526 0.168 0.012 DBMET03528 0.14 0.024 DBMET03529 0.182 0.01 DBMET03530 0.14 0.024 DBMET03531 | DBMET03530 | |
| 0.214 | 0.076 | 0.214 | Antimitotic | 0.173 0.101 DBMET00025 0.153 0.119 DBMET00026 0.189 0.09 DBMET00028 0.192 0.089 DBMET03526 0.194 0.087 DBMET03528 0.144 0.127 DBMET03529 0.197 0.086 DBMET03530 0.185 0.093 DBMET03531 | ||
| 0.164 | 0.027 | 0.471 | Protein kinase (CK2) inhibitor | 0.182 0.023 DBMET00025 0.471 0.003 DBMET03526 0.107 0.058 DBMET03528 0.119 0.049 DBMET03529 0.088 0.075 DBMET03530 0.13 0.043 DBMET03531 | DBMET03526 | |
| 0.158 | 0.025 | 0.226 | Activin receptor-like kinase 4 inhibitor | 0.189 0.016 DBMET00025 0.109 0.068 DBMET00026 0.114 0.061 DBMET00027 0.105 0.075 DBMET00028 0.112 0.064 DBMET03525 0.226 0.01 DBMET03527 0.13 0.041 DBMET03526 0.132 0.04 DBMET03528 0.155 0.026 DBMET03529 0.13 0.041 DBMET03530 0.149 0.029 DBMET03531 | DBMET03527 | |
| 0.137 | 0.005 | 0.155 | Polo-like kinase-2 inhibitor | 0.126 0.008 DBMET00025 0.112 0.016 DBMET00026 0.084 0.041 DBMET00027 0.117 0.012 DBMET00028 0.106 0.02 DBMET03525 0.155 0.004 DBMET03527 0.114 0.014 DBMET03526 0.129 0.007 DBMET03528 0.119 0.011 DBMET03529 0.124 0.009 DBMET03530 0.131 0.006 DBMET03531 | DBMET03527 | |
| 0.148 | 0.018 | 0.158 | MAP kinase 11 inhibitor | 0.157 0.016 DBMET00025 0.158 0.016 DBMET00028 0.094 0.039 DBMET03525 0.142 0.019 DBMET03526 0.112 0.029 DBMET03528 0.118 0.027 DBMET03529 0.103 0.034 DBMET03530 0.117 0.027 DBMET03531 | DBMET00028 | |
| 0.151 | 0.021 | 0.241 | Protein kinase C delta inhibitor | 0.17 0.014 DBMET00025 0.1 0.052 DBMET00026 0.195 0.009 DBMET00027 0.088 0.065 DBMET00028 0.112 0.042 DBMET03525 0.241 0.005 DBMET03527 0.148 0.022 DBMET03526 0.122 0.035 DBMET03528 0.144 0.024 DBMET03529 0.117 0.038 DBMET03530 0.152 0.02 DBMET03531 | DBMET03527 | |
| 0.141 | 0.011 | 0.143 | Focal adhesion kinase 1 inhibitor | 0.127 0.015 DBMET00025 0.082 0.048 DBMET00026 0.078 0.052 DBMET00027 0.113 0.021 DBMET00028 0.106 0.025 DBMET03525 0.139 0.012 DBMET03527 0.114 0.021 DBMET03526 0.127 0.015 DBMET03528 0.112 0.022 DBMET03529 0.143 0.011 DBMET03530 0.116 0.02 DBMET03531 | DBMET03530 | |
| 0.159 | 0.031 | 0.159 | MAP kinase kinase kinase inhibitor | 0.144 0.038 DBMET00025 0.14 0.04 DBMET00028 0.1 0.066 DBMET03527 0.139 0.041 DBMET03526 0.103 0.064 DBMET03528 0.09 0.076 DBMET03529 0.087 0.08 DBMET03530 0.108 0.059 DBMET03531 | ||
| 0.169 | 0.042 | 0.169 | Protein kinase (CK1) delta inhibitor | 0.163 0.046 DBMET00025 0.106 0.086 DBMET00026 0.1 0.092 DBMET00027 0.134 0.063 DBMET03527 0.143 0.057 DBMET03526 0.126 0.069 DBMET03528 0.118 0.074 DBMET03529 0.13 0.066 DBMET03530 0.141 0.059 DBMET03531 | ||
| 0.141 | 0.019 | 0.168 | I kappa B kinase inhibitor | 0.168 0.012 DBMET00025 0.109 0.032 DBMET00026 0.115 0.029 DBMET03527 0.133 0.021 DBMET03526 0.073 0.072 DBMET03528 0.087 0.052 DBMET03529 0.089 0.049 DBMET03531 | DBMET00025 | |
| 0.125 | 0.005 | 0.145 | CDK7/cyclin H inhibitor | 0.145 0.005 DBMET00025 0.077 0.009 DBMET00026 0.052 0.022 DBMET00027 0.084 0.007 DBMET00028 0.057 0.018 DBMET03525 0.052 0.022 DBMET03527 0.1 0.005 DBMET03526 0.089 0.007 DBMET03528 0.098 0.005 DBMET03529 0.086 0.007 DBMET03530 0.094 0.006 DBMET03531 | DBMET00025 | |
| 0.139 | 0.02 | 0.139 | AXL receptor tyrosine kinase inhibitor | 0.123 0.026 DBMET00025 0.076 0.067 DBMET00026 0.077 0.066 DBMET00028 0.129 0.024 DBMET03527 0.086 0.053 DBMET03526 0.1 0.04 DBMET03528 0.089 0.049 DBMET03529 0.091 0.047 DBMET03530 0.095 0.044 DBMET03531 | ||
| 0.16 | 0.042 | 0.16 | Epidermal growth factor receptor kinase inhibitor | 0.146 0.051 DBMET00025 0.126 0.067 DBMET00028 0.136 0.059 DBMET03526 0.142 0.054 DBMET03528 0.128 0.065 DBMET03529 0.14 0.055 DBMET03530 0.143 0.053 DBMET03531 | ||
| 0.14 | 0.023 | 0.14 | Janus tyrosine kinase 2 inhibitor | 0.139 0.023 DBMET00025 0.066 0.059 DBMET00026 0.064 0.062 DBMET00028 0.093 0.039 DBMET03527 0.07 0.055 DBMET03526 0.111 0.032 DBMET03528 0.105 0.034 DBMET03529 0.109 0.032 DBMET03530 0.111 0.032 DBMET03531 | ||
| 0.138 | 0.022 | 0.165 | Rho-associated kinase inhibitor | 0.165 0.016 DBMET00025 0.089 0.04 DBMET00026 0.078 0.048 DBMET00027 0.082 0.045 DBMET00028 0.069 0.056 DBMET03525 0.098 0.035 DBMET03526 0.088 0.041 DBMET03528 0.11 0.03 DBMET03529 0.084 0.043 DBMET03530 0.117 0.028 DBMET03531 | DBMET00025 | |
| 0.171 | 0.055 | 0.191 | CDC-like kinase 1 inhibitor | 0.159 0.063 DBMET00025 0.121 0.094 DBMET00026 0.191 0.041 DBMET03526 0.151 0.069 DBMET03528 0.138 0.079 DBMET03529 0.151 0.069 DBMET03530 0.136 0.081 DBMET03531 | DBMET03526 | |
| 0.236 | 0.12 | 0.306 | Nootropic | 0.219 0.135 DBMET00025 0.2 0.157 DBMET00027 0.306 0.072 DBMET03527 0.238 0.118 DBMET03528 0.205 0.152 DBMET03529 0.246 0.112 DBMET03530 0.212 0.143 DBMET03531 | DBMET03527 | |
| 0.143 | 0.029 | 0.368 | Protein kinase C mu inhibitor | 0.175 0.017 DBMET00025 0.112 0.047 DBMET00026 0.368 0.004 DBMET03527 0.104 0.054 DBMET03526 0.12 0.042 DBMET03528 0.153 0.025 DBMET03529 0.108 0.05 DBMET03530 0.187 0.014 DBMET03531 | DBMET03527 | |
| 0.117 | 0.006 | 0.144 | Cyclin A1 inhibitor | 0.144 0.004 DBMET00025 0.077 0.016 DBMET00026 0.091 0.01 DBMET00028 0.062 0.034 DBMET03525 0.085 0.012 DBMET03527 0.072 0.02 DBMET03526 0.08 0.014 DBMET03528 0.107 0.007 DBMET03529 0.078 0.015 DBMET03530 0.1 0.008 DBMET03531 | DBMET00025 | |
| 0.121 | 0.014 | 0.159 | MAP kinase kinase 8 inhibitor | 0.134 0.012 DBMET00025 0.159 0.008 DBMET00026 0.077 0.038 DBMET00028 0.132 0.012 DBMET03526 0.101 0.021 DBMET03528 0.111 0.018 DBMET03529 0.103 0.02 DBMET03530 0.108 0.018 DBMET03531 | DBMET00026 | |
| 0.13 | 0.023 | 0.133 | Janus tyrosine kinase 3 inhibitor | 0.133 0.023 DBMET00025 0.064 0.058 DBMET00026 0.066 0.056 DBMET03527 0.083 0.042 DBMET03526 0.089 0.038 DBMET03528 0.087 0.04 DBMET03529 0.085 0.041 DBMET03530 0.103 0.032 DBMET03531 | DBMET00025 | |
| 0.123 | 0.018 | 0.136 | CDK1/cyclin B inhibitor | 0.136 0.015 DBMET00025 0.097 0.026 DBMET00026 0.08 0.034 DBMET00028 0.122 0.018 DBMET03526 0.098 0.025 DBMET03528 0.106 0.022 DBMET03529 0.098 0.025 DBMET03530 0.122 0.018 DBMET03531 | DBMET00025 | |
| 0.146 | 0.044 | 0.146 | Beta amyloid protein antagonist | 0.112 0.075 DBMET00025 0.125 0.062 DBMET03527 0.135 0.052 DBMET03526 0.132 0.055 DBMET03528 0.112 0.075 DBMET03529 | ||
| 0.108 | 0.006 | 0.16 | Cyclin D3 inhibitor | 0.119 0.005 DBMET00025 0.061 0.016 DBMET00026 0.064 0.015 DBMET00028 0.046 0.023 DBMET03525 0.16 0.004 DBMET03527 0.077 0.011 DBMET03526 0.088 0.009 DBMET03528 0.097 0.008 DBMET03529 0.08 0.01 DBMET03530 0.093 0.008 DBMET03531 | DBMET03527 | |
| 0.116 | 0.014 | 0.128 | Tyrosine-protein kinase EMT inhibitor | 0.128 0.012 DBMET00025 0.058 0.039 DBMET00026 0.051 0.045 DBMET00028 0.098 0.018 DBMET03526 0.079 0.026 DBMET03528 0.087 0.022 DBMET03529 0.083 0.024 DBMET03530 0.09 0.021 DBMET03531 | DBMET00025 | |
| 0.112 | 0.011 | 0.165 | CDK4/cyclin D inhibitor | 0.132 0.009 DBMET00025 0.1 0.014 DBMET00026 0.069 0.028 DBMET00028 0.059 0.04 DBMET03525 0.165 0.006 DBMET03527 0.083 0.02 DBMET03526 0.098 0.015 DBMET03528 0.11 0.012 DBMET03529 0.096 0.016 DBMET03530 0.117 0.01 DBMET03531 | DBMET03527 | |
| 0.148 | 0.048 | 0.152 | TRKB antagonist | 0.139 0.054 DBMET00025 0.107 0.091 DBMET00026 0.152 0.046 DBMET03527 0.121 0.071 DBMET03528 0.107 0.091 DBMET03529 0.135 0.058 DBMET03530 0.132 0.06 DBMET03531 | DBMET03527 | |
| 0.123 | 0.024 | 0.134 | Protein kinase B gamma inhibitor | 0.134 0.021 DBMET00025 0.082 0.044 DBMET00026 0.083 0.044 DBMET03526 0.094 0.035 DBMET03528 0.097 0.034 DBMET03529 0.094 0.035 DBMET03530 0.11 0.028 DBMET03531 | DBMET00025 | |
| 0.116 | 0.018 | 0.125 | CDK2/cyclin E inhibitor | 0.125 0.017 DBMET00025 0.094 0.025 DBMET00026 0.071 0.034 DBMET00028 0.112 0.019 DBMET03526 0.087 0.028 DBMET03528 0.092 0.025 DBMET03529 0.082 0.029 DBMET03530 0.094 0.025 DBMET03531 | DBMET00025 | |
| 0.168 | 0.071 | 0.221 | Heat shock protein 90 alpha antagonist | 0.15 0.086 DBMET00025 0.221 0.038 DBMET00028 0.209 0.044 DBMET03526 0.167 0.072 DBMET03528 0.199 0.05 DBMET03530 0.142 0.096 DBMET03531 | DBMET00028 | |
| 0.158 | 0.061 | 0.2 | Vascular endothelial growth factor 3 antagonist | 0.166 0.057 DBMET00025 0.2 0.042 DBMET03527 0.128 0.087 DBMET03526 0.111 0.104 DBMET03528 0.125 0.089 DBMET03529 0.124 0.09 DBMET03531 | DBMET03527 | |
| 0.108 | 0.013 | 0.191 | CDK4/cyclin D1 inhibitor | 0.127 0.009 DBMET00025 0.11 0.012 DBMET00026 0.065 0.034 DBMET00028 0.191 0.005 DBMET03527 0.078 0.025 DBMET03526 0.094 0.017 DBMET03528 0.107 0.013 DBMET03529 0.092 0.018 DBMET03530 0.118 0.011 DBMET03531 | DBMET03527 | |
| 0.107 | 0.011 | 0.15 | Protein kinase C epsilon inhibitor | 0.108 0.011 DBMET00025 0.081 0.019 DBMET00026 0.052 0.039 DBMET00028 0.063 0.029 DBMET03525 0.15 0.006 DBMET03527 0.104 0.012 DBMET03526 0.084 0.018 DBMET03528 0.085 0.017 DBMET03529 0.078 0.02 DBMET03530 0.103 0.012 DBMET03531 | DBMET03527 | |
| 0.103 | 0.008 | 0.103 | Smo receptor antagonist | 0.095 0.009 DBMET00025 0.038 0.033 DBMET00027 0.047 0.025 DBMET00028 0.055 0.021 DBMET03525 0.061 0.018 DBMET03526 0.068 0.016 DBMET03528 0.062 0.018 DBMET03529 0.082 0.011 DBMET03530 0.073 0.014 DBMET03531 | ||
| 0.112 | 0.017 | 0.117 | T cell inhibitor | 0.11 0.018 DBMET00025 0.104 0.021 DBMET00026 0.081 0.063 DBMET00027 0.091 0.036 DBMET00028 0.086 0.046 DBMET03525 0.084 0.051 DBMET03527 0.117 0.015 DBMET03526 0.11 0.018 DBMET03528 0.103 0.022 DBMET03529 0.113 0.017 DBMET03530 0.099 0.025 DBMET03531 | DBMET03526 | |
| 0.105 | 0.012 | 0.105 | ZAP-70 protein tyrosine kinase inhibitor | 0.103 0.013 DBMET00025 0.076 0.04 DBMET00026 0.063 0.057 DBMET00027 0.093 0.02 DBMET00028 0.081 0.033 DBMET03525 0.067 0.052 DBMET03527 0.102 0.013 DBMET03526 0.098 0.015 DBMET03528 0.096 0.017 DBMET03529 0.099 0.015 DBMET03530 0.097 0.016 DBMET03531 | ||
| 0.127 | 0.034 | 0.127 | CDC-like kinase 3 inhibitor | 0.115 0.05 DBMET00025 0.111 0.058 DBMET00026 0.121 0.042 DBMET00027 0.102 0.074 DBMET00028 0.101 0.077 DBMET03525 0.109 0.06 DBMET03527 0.125 0.037 DBMET03526 0.12 0.043 DBMET03528 0.108 0.063 DBMET03529 0.12 0.043 DBMET03530 0.113 0.053 DBMET03531 | ||
| 0.11 | 0.017 | 0.126 | MAP3K7 inhibitor | 0.091 0.029 DBMET00025 0.091 0.029 DBMET00026 0.068 0.058 DBMET00028 0.07 0.055 DBMET03525 0.126 0.013 DBMET03527 0.077 0.043 DBMET03526 0.09 0.029 DBMET03528 0.073 0.049 DBMET03529 0.082 0.037 DBMET03530 0.08 0.04 DBMET03531 | DBMET03527 | |
| 0.135 | 0.044 | 0.156 | MAP kinase 13 inhibitor | 0.156 0.033 DBMET00025 0.102 0.078 DBMET00026 0.134 0.045 DBMET03526 0.119 0.057 DBMET03528 0.136 0.044 DBMET03529 0.11 0.067 DBMET03530 0.131 0.047 DBMET03531 | DBMET00025 | |
| 0.124 | 0.032 | 0.159 | Interleukin-1 receptor-associated protein kinase 4 inhibitor | 0.129 0.03 DBMET00025 0.159 0.018 DBMET00026 0.088 0.059 DBMET00028 0.095 0.05 DBMET03527 0.103 0.042 DBMET03526 0.088 0.059 DBMET03528 0.091 0.056 DBMET03529 0.093 0.052 DBMET03530 0.089 0.058 DBMET03531 | DBMET00026 | |
| 0.119 | 0.028 | 0.119 | ErbB-2 antagonist | 0.114 0.03 DBMET00025 0.079 0.049 DBMET00028 0.081 0.047 DBMET03526 0.094 0.038 DBMET03528 0.088 0.042 DBMET03529 0.092 0.039 DBMET03530 0.095 0.037 DBMET03531 | ||
| 0.098 | 0.009 | 0.115 | MAP kinase 7 inhibitor | 0.089 0.021 DBMET00025 0.079 0.048 DBMET00026 0.088 0.022 DBMET00028 0.084 0.033 DBMET03525 0.115 0.004 DBMET03527 0.079 0.048 DBMET03526 0.094 0.014 DBMET03528 0.085 0.029 DBMET03529 0.089 0.02 DBMET03530 0.086 0.026 DBMET03531 | DBMET03527 | |
| 0.118 | 0.032 | 0.12 | Leucine-rich repeat kinase 2 inhibitor | 0.099 0.043 DBMET00025 0.111 0.036 DBMET03527 0.105 0.04 DBMET03528 0.086 0.053 DBMET03529 0.12 0.031 DBMET03530 0.092 0.048 DBMET03531 | DBMET03530 | |
| 0.107 | 0.023 | 0.108 | Raf kinase C inhibitor | 0.108 0.023 DBMET00025 0.066 0.038 DBMET00027 0.101 0.025 DBMET03526 0.072 0.035 DBMET03528 0.083 0.031 DBMET03529 0.065 0.039 DBMET03530 0.088 0.029 DBMET03531 | DBMET00025 | |
| 0.114 | 0.031 | 0.149 | Phosphodiesterase 6D inhibitor | 0.091 0.073 DBMET00025 0.125 0.021 DBMET00026 0.149 0.01 DBMET03527 0.11 0.037 DBMET03528 0.115 0.03 DBMET03530 0.092 0.07 DBMET03531 | DBMET03527 | |
| 0.093 | 0.01 | 0.097 | Cyclin H inhibitor | 0.097 0.009 DBMET00025 0.075 0.023 DBMET00026 0.054 0.048 DBMET00027 0.08 0.019 DBMET00028 0.064 0.034 DBMET03525 0.097 0.009 DBMET03527 0.087 0.014 DBMET03526 0.084 0.015 DBMET03528 0.088 0.013 DBMET03529 0.082 0.018 DBMET03530 0.086 0.014 DBMET03531 | DBMET03527 | |
| 0.123 | 0.042 | 0.205 | Fibroblast growth factor 1 antagonist | 0.104 0.055 DBMET00025 0.122 0.042 DBMET00027 0.205 0.015 DBMET03527 0.102 0.056 DBMET03528 0.101 0.057 DBMET03530 0.107 0.052 DBMET03531 | DBMET03527 | |
| 0.135 | 0.054 | 0.151 | MAP kinase 12 inhibitor | 0.151 0.041 DBMET00025 0.101 0.097 DBMET00028 0.133 0.055 DBMET03526 0.121 0.068 DBMET03528 0.135 0.054 DBMET03529 0.113 0.079 DBMET03530 0.133 0.056 DBMET03531 | DBMET00025 | |
| 0.118 | 0.037 | 0.118 | Hepatocyte growth factor antagonist | 0.109 0.043 DBMET00025 0.09 0.063 DBMET00028 0.103 0.049 DBMET03527 0.099 0.052 DBMET03528 0.088 0.065 DBMET03529 0.092 0.06 DBMET03530 0.088 0.065 DBMET03531 | ||
| 0.114 | 0.036 | 0.114 | Epidermal growth factor antagonist | 0.097 0.047 DBMET00025 0.084 0.06 DBMET00028 0.091 0.052 DBMET03526 0.096 0.048 DBMET03528 0.079 0.067 DBMET03529 0.089 0.054 DBMET03530 0.086 0.058 DBMET03531 | ||
| 0.09 | 0.017 | 0.09 | Bruton tyrosine kinase inhibitor | 0.074 0.023 DBMET00025 0.063 0.031 DBMET03526 0.079 0.021 DBMET03528 0.063 0.032 DBMET03529 0.083 0.019 DBMET03530 0.07 0.026 DBMET03531 | ||
| 0.113 | 0.042 | 0.145 | MAP kinase kinase 1 inhibitor | 0.091 0.069 DBMET00025 0.145 0.018 DBMET03527 0.134 0.024 DBMET03526 0.087 0.075 DBMET03528 0.098 0.059 DBMET03531 | DBMET03527 | |
| 0.107 | 0.037 | 0.107 | ErbB-3 antagonist | 0.082 0.059 DBMET00025 0.08 0.061 DBMET00028 0.077 0.065 DBMET03527 0.085 0.055 DBMET03526 0.085 0.054 DBMET03528 0.08 0.061 DBMET03530 | ||
| 0.177 | 0.109 | 0.315 | Potassium channel blocker | 0.166 0.119 DBMET00025 0.315 0.042 DBMET03527 0.15 0.135 DBMET03528 0.149 0.136 DBMET03530 | DBMET03527 | |
| 0.081 | 0.014 | 0.114 | Protein kinase C theta inhibitor | 0.086 0.011 DBMET00025 0.09 0.01 DBMET00027 0.064 0.031 DBMET00028 0.066 0.028 DBMET03525 0.114 0.006 DBMET03527 0.06 0.037 DBMET03526 0.069 0.024 DBMET03528 0.072 0.021 DBMET03529 0.068 0.026 DBMET03530 0.079 0.015 DBMET03531 | DBMET03527 | |
| 0.12 | 0.055 | 0.14 | CDK3/cyclin E inhibitor | 0.128 0.046 DBMET00025 0.097 0.094 DBMET00028 0.14 0.034 DBMET03526 0.106 0.077 DBMET03528 0.113 0.065 DBMET03529 0.105 0.079 DBMET03530 0.121 0.055 DBMET03531 | DBMET03526 | |
| 0.079 | 0.018 | 0.119 | Toll-Like receptor 8 antagonist | 0.091 0.012 DBMET00025 0.056 0.035 DBMET00026 0.119 0.005 DBMET03527 0.053 0.038 DBMET03528 0.05 0.041 DBMET03529 0.061 0.03 DBMET03531 | DBMET03527 | |
| 0.092 | 0.031 | 0.108 | CDK2/cyclin E2 inhibitor | 0.108 0.026 DBMET00025 0.075 0.043 DBMET00026 0.074 0.044 DBMET00028 0.097 0.029 DBMET03526 0.071 0.047 DBMET03528 0.079 0.039 DBMET03529 0.067 0.052 DBMET03530 0.078 0.041 DBMET03531 | DBMET00025 | |
| 0.142 | 0.083 | 0.157 | Heat shock protein 90 antagonist | 0.157 0.068 DBMET00028 0.127 0.101 DBMET03527 0.133 0.094 DBMET03526 0.134 0.092 DBMET03528 0.149 0.075 DBMET03530 0.118 0.117 DBMET03531 | DBMET00028 | |
| 0.116 | 0.062 | 0.156 | Cyclin-dependent kinase 5 inhibitor | 0.128 0.053 DBMET00025 0.123 0.056 DBMET00028 0.156 0.037 DBMET03526 0.095 0.08 DBMET03529 0.11 0.067 DBMET03531 | DBMET03526 | |
| 0.127 | 0.079 | 0.171 | Interleukin 1 antagonist | 0.135 0.071 DBMET00025 0.171 0.046 DBMET03526 0.117 0.093 DBMET03531 | DBMET03526 | |
| 0.082 | 0.035 | 0.103 | I kappa B kinase 1 inhibitor | 0.103 0.021 DBMET00025 0.087 0.031 DBMET03527 0.089 0.029 DBMET03526 0.064 0.058 DBMET03528 0.08 0.037 DBMET03529 0.064 0.058 DBMET03530 0.075 0.041 DBMET03531 | DBMET00025 | |
| 0.125 | 0.078 | 0.287 | Toll-Like receptor antagonist | 0.114 0.094 DBMET00025 0.287 0.008 DBMET03527 | DBMET03527 | |
| 0.115 | 0.069 | 0.183 | Interleukin 8 antagonist | 0.113 0.072 DBMET00025 0.183 0.018 DBMET03527 0.129 0.051 DBMET03526 0.113 0.072 DBMET03528 | DBMET03527 | |
| 0.082 | 0.036 | 0.085 | Tyk2 inhibitor | 0.085 0.034 DBMET00025 0.061 0.047 DBMET03531 | DBMET00025 | |
| 0.051 | 0.006 | 0.055 | CDK6/cyclin D3 inhibitor | 0.055 0.005 DBMET00025 0.038 0.017 DBMET00026 0.037 0.017 DBMET00028 0.035 0.022 DBMET03525 0.05 0.006 DBMET03527 0.045 0.009 DBMET03526 0.048 0.007 DBMET03528 0.053 0.005 DBMET03529 0.046 0.008 DBMET03530 0.052 0.006 DBMET03531 | DBMET00025 | |
| 0.073 | 0.029 | 0.088 | I kappa B kinase 2 inhibitor | 0.088 0.018 DBMET00025 0.063 0.041 DBMET00026 0.087 0.018 DBMET03527 0.071 0.031 DBMET03526 | DBMET00025 | |
| 0.097 | 0.055 | 0.244 | Protein kinase C zeta inhibitor | 0.09 0.066 DBMET00025 0.115 0.035 DBMET00026 0.244 0.008 DBMET03527 | DBMET03527 | |
| 0.058 | 0.016 | 0.073 | CDK5/p25 inhibitor | 0.06 0.015 DBMET00025 0.073 0.01 DBMET03526 0.038 0.033 DBMET03528 0.04 0.03 DBMET03529 0.061 0.015 DBMET03531 | DBMET03526 | |
| 0.103 | 0.062 | 0.123 | Gastric antisecretory | 0.123 0.041 DBMET00028 0.092 0.075 DBMET03527 0.091 0.077 DBMET03526 | DBMET00028 | |
| 0.11 | 0.071 | 0.152 | Interleukin 1b antagonist | 0.112 0.069 DBMET00025 0.094 0.088 DBMET03525 0.152 0.039 DBMET03526 0.105 0.075 DBMET03531 | DBMET03526 | |
| 0.091 | 0.056 | 0.129 | Pim-3 kinase inhibitor | 0.121 0.03 DBMET00025 0.088 0.061 DBMET00026 0.129 0.026 DBMET03527 0.082 0.073 DBMET03526 0.088 0.061 DBMET03529 0.087 0.062 DBMET03531 | DBMET03527 | |
| 0.068 | 0.034 | 0.085 | Cyclin B1 inhibitor | 0.078 0.023 DBMET00025 0.085 0.018 DBMET03527 0.077 0.024 DBMET03526 0.059 0.044 DBMET03528 0.07 0.032 DBMET03529 0.068 0.035 DBMET03531 | DBMET03527 | |
| 0.066 | 0.034 | 0.134 | Cyclin D1 inhibitor | 0.062 0.039 DBMET00025 0.134 0.004 DBMET03527 | DBMET03527 | |
| 0.06 | 0.031 | 0.078 | MAP kinase kinase 9 inhibitor | 0.078 0.016 DBMET00025 0.053 0.044 DBMET00026 0.074 0.018 DBMET03526 0.055 0.039 DBMET03529 0.054 0.041 DBMET03531 | DBMET00025 | |
| 0.07 | 0.041 | 0.208 | 5 Hydroxytryptamine 3A antagonist | 0.063 0.052 DBMET00025 0.208 0.004 DBMET03527 0.062 0.053 DBMET03528 | DBMET03527 | |
| 0.07 | 0.042 | 0.082 | Fibroblast growth factor 2 antagonist | 0.082 0.032 DBMET03527 | DBMET03527 | |
| 0.084 | 0.057 | 0.113 | Protein kinase A inhibitor | 0.106 0.041 DBMET00025 0.083 0.058 DBMET00026 0.102 0.044 DBMET03527 0.113 0.037 DBMET03526 0.081 0.059 DBMET03529 0.092 0.051 DBMET03531 | DBMET03526 | |
| 0.101 | 0.074 | 0.143 | EphA2 antagonist | 0.143 0.034 DBMET03527 0.099 0.077 DBMET03528 0.099 0.077 DBMET03529 0.11 0.065 DBMET03531 | DBMET03527 | |
| 0.067 | 0.044 | 0.081 | Histone deacetylase inhibitor | 0.058 0.057 DBMET00025 0.081 0.03 DBMET03528 0.068 0.042 DBMET03529 0.068 0.043 DBMET03531 | DBMET03528 | |
| 0.07 | 0.047 | 0.078 | Transforming growth factor antagonist | 0.078 0.037 DBMET00025 0.066 0.054 DBMET03526 0.069 0.049 DBMET03529 0.063 0.061 DBMET03531 | DBMET00025 | |
| 0.054 | 0.032 | 0.065 | Chemokine receptor agonist | 0.065 0.023 DBMET00025 0.049 0.036 DBMET00026 0.054 0.032 DBMET00028 0.053 0.033 DBMET03525 0.043 0.041 DBMET03530 0.061 0.026 DBMET03531 | DBMET00025 | |
| 0.135 | 0.114 | 0.135 | Interleukin 6 antagonist | 0.13 0.124 DBMET00025 0.133 0.118 DBMET00026 | ||
| 0.069 | 0.049 | 0.174 | Protein kinase C beta inhibitor | 0.069 0.05 DBMET00025 0.087 0.022 DBMET00026 0.174 0.004 DBMET03527 | DBMET03527 | |
| 0.056 | 0.036 | 0.087 | Nicotinic alpha7 receptor agonist | 0.048 0.046 DBMET00025 0.057 0.034 DBMET00026 0.087 0.015 DBMET03527 | DBMET03527 | |
| 0.068 | 0.048 | 0.203 | Protein kinase C alpha inhibitor | 0.079 0.034 DBMET00025 0.069 0.045 DBMET00026 0.203 0.005 DBMET03527 0.067 0.048 DBMET03526 0.065 0.052 DBMET03529 0.071 0.043 DBMET03531 | DBMET03527 | |
| 0.056 | 0.037 | 0.197 | Protein kinase C eta inhibitor | 0.05 0.044 DBMET00025 0.051 0.043 DBMET00026 0.197 0.004 DBMET03527 0.059 0.035 DBMET03526 0.063 0.032 DBMET03531 | DBMET03527 | |
| 0.032 | 0.015 | 0.066 | CDK4/cyclin D3 inhibitor | 0.032 0.015 DBMET00025 0.066 0.005 DBMET03527 | DBMET03527 | |
| 0.08 | 0.063 | 0.192 | MAP-kinase-activated kinase inhibitor | 0.112 0.03 DBMET00025 0.192 0.006 DBMET03527 0.104 0.036 DBMET03529 0.144 0.017 DBMET03531 | DBMET03527 | |
| 0.072 | 0.056 | 0.106 | Phosphodiesterase VI inhibitor | 0.083 0.036 DBMET00026 0.106 0.017 DBMET03527 0.073 0.055 DBMET03530 | DBMET03527 | |
| 0.08 | 0.064 | 0.09 | Transforming growth factor beta 3 antagonist | 0.08 0.064 DBMET00025 0.085 0.05 DBMET00027 0.09 0.038 DBMET03527 0.079 0.068 DBMET03528 0.079 0.069 DBMET03529 | DBMET03527 | |
| 0.041 | 0.026 | 0.048 | Histone deacetylase class I inhibitor | 0.035 0.033 DBMET00025 0.048 0.021 DBMET03528 0.038 0.028 DBMET03529 0.035 0.032 DBMET03531 | DBMET03528 | |
| 0.086 | 0.073 | 0.154 | Pim-1 kinase inhibitor | 0.113 0.047 DBMET00025 0.154 0.026 DBMET03527 0.113 0.047 DBMET03526 0.083 0.077 DBMET03529 0.093 0.064 DBMET03531 | DBMET03527 | |
| 0.092 | 0.081 | 0.114 | mTOR complex 1 inhibitor | 0.108 0.047 DBMET03528 0.114 0.037 DBMET03529 0.112 0.04 DBMET03530 0.107 0.047 DBMET03531 | DBMET03529 | |
| 0.038 | 0.029 | 0.081 | Protein kinase (CK1) epsilon inhibitor | 0.039 0.027 DBMET00025 0.081 0.005 DBMET03527 | DBMET03527 | |
| 0.052 | 0.043 | 0.067 | Cyclin B inhibitor | 0.061 0.03 DBMET00025 0.067 0.024 DBMET03527 0.062 0.03 DBMET03526 0.054 0.04 DBMET03529 0.051 0.044 DBMET03531 | DBMET03527 | |
| 0.045 | 0.037 | 0.045 | Proto-oncogene tyrosine-protein kinase Met inhibitor | 0.043 0.039 DBMET00025 | ||
| 0.048 | 0.04 | 0.052 | H+/K+-transporting ATPase inhibitor | 0.048 0.04 DBMET00025 0.047 0.041 DBMET00028 0.052 0.034 DBMET03526 | DBMET03526 | |
| 0.068 | 0.061 | 0.175 | MAP-kinase-activated kinase 2 inhibitor | 0.099 0.029 DBMET00025 0.175 0.006 DBMET03527 0.088 0.037 DBMET03529 0.131 0.016 DBMET03531 | DBMET03527 | |
| 0.032 | 0.026 | 0.038 | CXC chemokine receptor agonist | 0.038 0.018 DBMET00025 0.03 0.027 DBMET00028 0.031 0.027 DBMET03525 0.037 0.021 DBMET03531 | DBMET00025 | |
| 0.051 | 0.046 | 0.063 | Cyclin B2 inhibitor | 0.06 0.032 DBMET00025 0.061 0.031 DBMET03527 0.063 0.029 DBMET03526 0.053 0.042 DBMET03529 0.051 0.045 DBMET03531 | DBMET03526 | |
| 0.086 | 0.081 | 0.11 | Interleukin 12 antagonist | 0.088 0.077 DBMET00025 0.11 0.04 DBMET03526 | DBMET03526 | |
| 0.052 | 0.049 | 0.081 | Fibroblast growth factor 4 antagonist | 0.081 0.017 DBMET03527 0.081 0.017 DBMET03528 0.064 0.032 DBMET03529 0.065 0.032 DBMET03530 | DBMET03528 | |
| 0.118 | 0.119 | 0.164 | MAP3K9 inhibitor | 0.124 0.106 DBMET00025 0.139 0.077 DBMET00026 0.129 0.097 DBMET03527 0.129 0.095 DBMET03526 0.164 0.042 DBMET03531 | DBMET03531 | |
| 0.04 | 0.041 | 0.042 | Heme oxygenase inhibitor | 0.042 0.031 DBMET00025 | DBMET00025 | |
| 0.158 | 0.159 | 0.245 | ErbB-1 antagonist | 0.245 0.054 DBMET03527 | DBMET03527 | |
| 0.042 | 0.045 | 0.054 | Transforming growth factor beta 1 antagonist | 0.054 0.03 DBMET00025 | DBMET00025 | |
| 0.101 | 0.105 | 0.162 | Transcription factor STAT6 inhibitor | 0.162 0.016 DBMET03527 | DBMET03527 | |
| 0.047 | 0.052 | 0.077 | Pim-2 kinase inhibitor | 0.059 0.032 DBMET00025 0.049 0.047 DBMET00026 0.077 0.022 DBMET03527 0.049 0.048 DBMET03531 | DBMET03527 | |
| 0.053 | 0.059 | 0.09 | Transcription factor AP-1 inhibitor | 0.061 0.043 DBMET00027 0.09 0.016 DBMET03526 | DBMET03526 | |
| 0.064 | 0.07 | 0.068 | Protein kinase B beta inhibitor | 0.068 0.061 DBMET00025 | DBMET00025 | |
| 0.045 | 0.052 | 0.062 | Phosphodiesterase 7A inhibitor | 0.052 0.035 DBMET00026 0.062 0.018 DBMET03527 0.056 0.027 DBMET03528 0.054 0.032 DBMET03529 0.058 0.024 DBMET03530 0.052 0.035 DBMET03531 | DBMET03527 | |
| 0.067 | 0.075 | 0.209 | Acetylcholine nicotinic agonist | 0.079 0.058 DBMET00025 0.088 0.048 DBMET00026 0.209 0.007 DBMET03527 | DBMET03527 | |
| 0.071 | 0.083 | 0.109 | Phosphodiesterase 11A inhibitor | 0.079 0.062 DBMET03528 0.109 0.026 DBMET03530 0.079 0.061 DBMET03531 | DBMET03530 | |
| 0.071 | 0.083 | 0.109 | Phosphodiesterase XI inhibitor | 0.079 0.062 DBMET03528 0.109 0.026 DBMET03530 0.079 0.061 DBMET03531 | DBMET03530 | |
| 0.048 | 0.062 | 0.229 | Alpha 2 adrenoreceptor agonist | 0.065 0.037 DBMET00025 0.229 0.004 DBMET03527 | DBMET03527 | |
| 0.173 | 0.187 | 0.346 | Hypoxia-inducible factor 1 alpha inhibitor | 0.346 0.046 DBMET03527 | DBMET03527 | |
| 0.053 | 0.068 | 0.198 | Cyclin B3 inhibitor | 0.065 0.05 DBMET00025 0.198 0.006 DBMET03527 | DBMET03527 | |
| 0.01 | 0.028 | 0.03 | Cyclin D2 inhibitor | 0.03 0.003 DBMET03527 | DBMET03527 | |
| 0.038 | 0.056 | 0.064 | Potassium channel (Inward rectifier) blocker | 0.064 0.021 DBMET03527 | DBMET03527 | |
| 0.073 | 0.092 | 0.108 | Check point kinase 2 inhibitor | 0.108 0.058 DBMET00025 0.106 0.06 DBMET03526 0.084 0.079 DBMET03531 | DBMET00025 | |
| 0.05 | 0.07 | 0.316 | 5 Hydroxytryptamine 3 agonist | 0.316 0.003 DBMET03527 | DBMET03527 | |
| 0.04 | 0.06 | 0.136 | Nicotinic neuronal receptor agonist | 0.053 0.043 DBMET00025 0.056 0.039 DBMET00026 0.136 0.007 DBMET03527 | DBMET03527 | |
| 0.088 | 0.11 | 0.132 | Nav1.5 sodium channel blocker | 0.132 0.041 DBMET03527 | DBMET03527 | |
| 0.038 | 0.059 | 0.065 | mTOR inhibitor | 0.065 0.025 DBMET03527 | DBMET03527 | |
| 0.017 | 0.039 | 0.203 | 5 Hydroxytryptamine 1F agonist | 0.203 0.003 DBMET03527 | DBMET03527 | |
| 0.045 | 0.075 | 0.233 | Toll-Like receptor 7 antagonist | 0.233 0.004 DBMET03527 | DBMET03527 | |
| 0.144 | 0.178 | 0.152 | MAP kinase kinase 5 inhibitor | 0.152 0.144 DBMET03531 | DBMET03531 | |
| 0.069 | 0.103 | 0.081 | Breast cancer-resistant protein inhibitor | 0.081 0.079 DBMET03526 | DBMET03526 | |
| 0.032 | 0.069 | 0.069 | Potassium channel small-conductance Ca-activated blocker | 0.069 0.013 DBMET03527 | DBMET03527 | |
| 0.168 | 0.206 | 0.203 | Immunomodulator | 0.203 0.16 DBMET03526 | DBMET03526 | |
| 0.04 | 0.079 | 0.083 | Phosphodiesterase VII inhibitor | 0.083 0.023 DBMET03527 0.059 0.048 DBMET03528 0.063 0.043 DBMET03530 | DBMET03527 | |
| 0.05 | 0.091 | 0.084 | Telomerase inhibitor | 0.084 0.042 DBMET03527 | DBMET03527 | |
| 0.012 | 0.053 | 0.033 | Alpha 2d adrenoreceptor agonist | 0.033 0.008 DBMET00027 0.027 0.01 DBMET03527 | DBMET00027 | |
| 0.022 | 0.063 | 0.031 | Purinergic P2Y2 antagonist | 0.031 0.027 DBMET03526 | DBMET03526 | |
| 0.017 | 0.059 | 0.022 | CC chemokine 8 receptor antagonist | 0.022 0.02 DBMET00028 | DBMET00028 | |
| 0.026 | 0.074 | 0.087 | Acid-sensing ion channel blocker | 0.087 0.004 DBMET03527 | DBMET03527 | |
| 0.046 | 0.094 | 0.12 | Phosphodiesterase 1A inhibitor | 0.12 0.007 DBMET03527 | DBMET03527 | |
| 0.024 | 0.074 | 0.071 | Protein kinase (CK2) beta inhibitor | 0.071 0.004 DBMET03527 0.037 0.016 DBMET03526 | DBMET03527 | |
| 0.06 | 0.112 | 0.104 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.104 0.035 DBMET03526 | DBMET03526 | |
| 0.035 | 0.087 | 0.063 | CC chemokine receptor 2B antagonist | 0.063 0.016 DBMET03527 | DBMET03527 | |
| 0.067 | 0.121 | 0.088 | DNA directed RNA polymerase inhibitor | 0.088 0.072 DBMET00028 0.084 0.078 DBMET03531 | DBMET00028 | |
| 0.086 | 0.141 | 0.362 | Toll-Like receptor 9 antagonist | 0.362 0.005 DBMET03527 | DBMET03527 | |
| 0.02 | 0.075 | 0.027 | Glucosylceramidase stimulant | 0.027 0.018 DBMET03527 | DBMET03527 | |
| 0.037 | 0.094 | 0.104 | Protein kinase C iota inhibitor | 0.104 0.018 DBMET03527 | DBMET03527 | |
| 0.024 | 0.084 | 0.052 | Protein kinase C beta I inhibitor | 0.052 0.004 DBMET03527 | DBMET03527 | |
| 0.042 | 0.103 | 0.144 | Check point kinase 1 inhibitor | 0.06 0.059 DBMET00025 0.144 0.016 DBMET03527 | DBMET03527 | |
| 0.111 | 0.174 | 0.127 | CC chemokine 6 receptor antagonist | 0.127 0.081 DBMET03526 | DBMET03526 | |
| 0.045 | 0.11 | 0.091 | Potassium channel (ATP-sensitive) blocker | 0.091 0.02 DBMET03526 | DBMET03526 | |
| 0.045 | 0.11 | 0.137 | Protein kinase (CaMK, MLCK, PhK, SNF, KIN, NIM1, MAPKAP, POLO, CHK, ULK, RSK-2nd domain) inhibitor | 0.068 0.063 DBMET00025 0.137 0.022 DBMET03527 | DBMET03527 | |
| 0.031 | 0.098 | 0.254 | 5 Hydroxytryptamine 3 antagonist | 0.254 0.004 DBMET03527 | DBMET03527 | |
| 0.107 | 0.175 | 0.353 | Aryl hydrocarbon receptor agonist | 0.353 0.047 DBMET03526 | DBMET03526 | |
| 0.027 | 0.095 | 0.092 | Dopamine D4 agonist | 0.077 0.02 DBMET00028 0.092 0.016 DBMET03527 | DBMET03527 | |
| 0.019 | 0.087 | 0.044 | DNA gyrase subunit B inhibitor | 0.044 0.019 DBMET03526 | DBMET03526 | |
| 0.172 | 0.242 | 0.554 | Toll-Like receptor 7 agonist | 0.554 0.023 DBMET00028 | DBMET00028 | |
| 0.025 | 0.098 | 0.035 | ATM kinase inhibitor | 0.035 0.028 DBMET03527 | DBMET03527 | |
| 0.021 | 0.095 | 0.036 | ATR kinase inhibitor | 0.036 0.017 DBMET03527 | DBMET03527 | |
| 0.016 | 0.091 | 0.042 | Cyclophilin A inhibitor | 0.031 0.022 DBMET03528 0.042 0.01 DBMET03530 | DBMET03530 | |
| 0.169 | 0.244 | 0.55 | Toll-Like receptor agonist | 0.55 0.024 DBMET00028 | DBMET00028 | |
| 0.022 | 0.098 | 0.035 | Transforming growth factor beta 2 antagonist | 0.035 0.02 DBMET03527 | DBMET03527 | |
| 0.021 | 0.099 | 0.053 | Melanin-concentrating hormone receptor 1 antagonist | 0.053 0.036 DBMET03527 | DBMET03527 | |
| 0.021 | 0.099 | 0.044 | Vanilloid 4 antagonist | 0.044 0.009 DBMET03527 | DBMET03527 | |
| 0.039 | 0.12 | 0.103 | Heat shock protein 90 beta antagonist | 0.103 0.01 DBMET03527 | DBMET03527 | |
| 0.03 | 0.113 | 0.096 | Bromodomain-containing protein 4 inhibitor | 0.096 0.014 DBMET03527 | DBMET03527 | |
| 0.03 | 0.114 | 0.252 | CXC chemokine 4 receptor antagonist | 0.252 0.007 DBMET03527 0.069 0.037 DBMET03529 0.069 0.037 DBMET03531 | DBMET03527 | |
| 0.012 | 0.097 | 0.024 | Histone-lysine N-methyltransferase EZH2 inhibitor | 0.024 0.005 DBMET03527 | DBMET03527 | |
| 0.105 | 0.191 | 0.179 | CF transmembrane conductance regulator agonist | 0.15 0.075 DBMET03527 0.179 0.037 DBMET03526 | DBMET03526 | |
| 0.056 | 0.142 | 0.202 | Falcipain 3 inhibitor | 0.202 0.017 DBMET03527 | DBMET03527 | |
| 0.018 | 0.105 | 0.064 | Protein kinase C beta II inhibitor | 0.064 0.004 DBMET03527 | DBMET03527 | |
| 0.02 | 0.107 | 0.047 | Adenosine A2b receptor antagonist | 0.047 0.038 DBMET03527 | DBMET03527 | |
| 0.034 | 0.123 | 0.259 | Alpha adrenoreceptor agonist | 0.259 0.005 DBMET03527 | DBMET03527 | |
| 0.029 | 0.118 | 0.11 | Lysine-specific demethylase 1A inhibitor | 0.11 0.005 DBMET03527 | DBMET03527 | |
| 0.038 | 0.13 | 0.092 | CXC chemokine receptor antagonist | 0.092 0.029 DBMET03527 0.066 0.055 DBMET03531 | DBMET03527 | |
| 0.031 | 0.127 | 0.155 | Prostaglandin-E synthase inhibitor | 0.155 0.01 DBMET03526 | DBMET03526 | |
| 0.029 | 0.126 | 0.216 | Histamine H4 receptor antagonist | 0.216 0.003 DBMET03527 | DBMET03527 | |
| 0.044 | 0.142 | 0.068 | Histone deacetylase SIRT3 inhibitor | 0.068 0.031 DBMET03527 0.058 0.055 DBMET03531 | DBMET03527 | |
| 0.01 | 0.108 | 0.101 | Motilin receptor agonist | 0.101 0.004 DBMET03527 | DBMET03527 | |
| 0.094 | 0.193 | 0.161 | Hemostatic | 0.161 0.056 DBMET03527 0.145 0.074 DBMET03526 | DBMET03527 | |
| 0.214 | 0.313 | 0.346 | Antiinflammatory | 0.346 0.176 DBMET03526 | DBMET03526 | |
| 0.036 | 0.135 | 0.068 | DNA gyrase inhibitor | 0.068 0.039 DBMET03526 | DBMET03526 | |
| 0.076 | 0.177 | 0.135 | Interleukin 4 antagonist | 0.135 0.065 DBMET03526 | DBMET03526 | |
| 0.017 | 0.119 | 0.04 | Purinergic P2X3 antagonist | 0.04 0.017 DBMET00026 | DBMET00026 | |
| 0.107 | 0.209 | 0.152 | MAP kinase kinase 4 inhibitor | 0.138 0.089 DBMET00026 0.152 0.058 DBMET03526 | DBMET03526 | |
| 0.013 | 0.116 | 0.03 | Phosphodiesterase 6A inhibitor | 0.03 0.007 DBMET03527 | DBMET03527 | |
| 0.063 | 0.168 | 0.199 | Carbonic anhydrase XV inhibitor | 0.099 0.068 DBMET03527 0.199 0.019 DBMET03526 | DBMET03526 | |
| 0.021 | 0.128 | 0.051 | Purinergic P2X antagonist | 0.051 0.031 DBMET03528 | DBMET03528 | |
| 0.013 | 0.122 | 0.034 | Purinergic P2X7 antagonist | 0.034 0.026 DBMET03528 | DBMET03528 | |
| 0.197 | 0.313 | 0.494 | 5 Hydroxytryptamine release inhibitor | 0.244 0.236 DBMET00025 0.354 0.112 DBMET03527 0.494 0.034 DBMET03526 | DBMET03526 | |
| 0.142 | 0.259 | 0.245 | Transcription factor STAT inhibitor | 0.198 0.141 DBMET03527 0.245 0.09 DBMET03526 | DBMET03526 | |
| 0.09 | 0.209 | 0.158 | Interleukin antagonist | 0.158 0.112 DBMET03526 | DBMET03526 | |
| 0.012 | 0.135 | 0.051 | Phosphodiesterase 6B inhibitor | 0.051 0.007 DBMET03527 | DBMET03527 | |
| 0.024 | 0.147 | 0.201 | Nicotinic receptor alpha4 subunit antagonist | 0.201 0.004 DBMET03527 | DBMET03527 | |
| 0.006 | 0.13 | 0.11 | Histamine H4 receptor agonist | 0.11 0.003 DBMET03527 | DBMET03527 | |
| 0.127 | 0.261 | 0.324 | Gastrin inhibitor | 0.324 0.019 DBMET03527 | DBMET03527 | |
| 0.011 | 0.146 | 0.032 | Phosphodiesterase 6H inhibitor | 0.032 0.006 DBMET03527 | DBMET03527 | |
| 0.011 | 0.146 | 0.032 | Phosphodiesterase 6G inhibitor | 0.032 0.006 DBMET03527 | DBMET03527 | |
| 0.085 | 0.222 | 0.568 | HERG channel blocker | 0.568 0.01 DBMET03527 | DBMET03527 | |
| 0.007 | 0.144 | 0.056 | Cyclin E2 inhibitor | 0.056 0.008 DBMET03527 | DBMET03527 | |
| 0.009 | 0.148 | 0.086 | Potassium channel small-conductance Ca-activated activator | 0.086 0.005 DBMET03527 | DBMET03527 | |
| 0.03 | 0.171 | 0.061 | Phosphodiesterase 6C inhibitor | 0.061 0.008 DBMET03527 | DBMET03527 | |
| 0.052 | 0.195 | 0.112 | Phosphodiesterase 7B inhibitor | 0.112 0.044 DBMET03527 | DBMET03527 | |
| 0.02 | 0.166 | 0.229 | 5 Hydroxytryptamine 1D antagonist | 0.229 0.005 DBMET03527 | DBMET03527 | |
| 0.081 | 0.227 | 0.221 | NOS3 expression enhancer | 0.145 0.077 DBMET03526 0.136 0.088 DBMET03528 0.221 0.034 DBMET03529 0.121 0.114 DBMET03530 | DBMET03529 | |
| 0.046 | 0.193 | 0.137 | Caspase 7 inhibitor | 0.137 0.01 DBMET03527 | DBMET03527 | |
| 0.011 | 0.159 | 0.038 | Purinergic P2Y14 antagonist | 0.038 0.013 DBMET03526 | DBMET03526 | |
| 0.031 | 0.182 | 0.308 | Alpha 2a adrenoreceptor antagonist | 0.308 0.006 DBMET03527 | DBMET03527 | |
| 0.057 | 0.21 | 0.081 | Hematopoietic | 0.081 0.071 DBMET03527 | DBMET03527 | |
| 0.006 | 0.163 | 0.021 | CDK2/cyclin A3 inhibitor | 0.021 0.005 DBMET03527 | DBMET03527 | |
| 0.011 | 0.168 | 0.037 | MAP3K8 inhibitor | 0.037 0.009 DBMET03527 | DBMET03527 | |
| 0.021 | 0.185 | 0.221 | Histamine agonist | 0.221 0.004 DBMET03527 | DBMET03527 | |
| 0.008 | 0.174 | 0.155 | 5 Hydroxytryptamine 3B antagonist | 0.155 0.004 DBMET03527 | DBMET03527 | |
| 0.021 | 0.189 | 0.056 | Purinergic P2 antagonist | 0.056 0.052 DBMET03528 | DBMET03528 | |
| 0.045 | 0.214 | 0.252 | Alpha 2c adrenoreceptor antagonist | 0.252 0.01 DBMET03527 | DBMET03527 | |
| 0.035 | 0.204 | 0.261 | Acetylcholine agonist | 0.261 0.008 DBMET03527 | DBMET03527 | |
| 0.048 | 0.219 | 0.145 | Bromodomain-containing protein 2 inhibitor | 0.145 0.01 DBMET03527 | DBMET03527 | |
| 0.032 | 0.203 | 0.158 | 5 Hydroxytryptamine 5A antagonist | 0.158 0.007 DBMET03527 | DBMET03527 | |
| 0.044 | 0.216 | 0.307 | Alpha 2b adrenoreceptor antagonist | 0.307 0.009 DBMET03527 | DBMET03527 | |
| 0.028 | 0.201 | 0.154 | 5 Hydroxytryptamine 5 antagonist | 0.154 0.007 DBMET03527 | DBMET03527 | |
| 0.023 | 0.2 | 0.116 | Phosphodiesterase 5A inhibitor | 0.116 0.02 DBMET03527 | DBMET03527 | |
| 0.015 | 0.192 | 0.052 | Bromodomain-containing protein 3 inhibitor | 0.052 0.031 DBMET03527 | DBMET03527 | |
| 0.028 | 0.21 | 0.1 | Phosphodiesterase 1B inhibitor | 0.1 0.014 DBMET03527 | DBMET03527 | |
| 0.075 | 0.257 | 0.49 | Potassium channel (Voltage-sensitive) blocker | 0.49 0.015 DBMET03527 | DBMET03527 | |
| 0.022 | 0.204 | 0.116 | Phosphodiesterase V inhibitor | 0.116 0.02 DBMET03527 | DBMET03527 | |
| 0.023 | 0.206 | 0.225 | Nicotinic alpha4beta2 receptor antagonist | 0.225 0.004 DBMET03527 | DBMET03527 | |
| 0.039 | 0.222 | 0.126 | Histamine H2 receptor antagonist | 0.126 0.018 DBMET03527 | DBMET03527 | |
| 0.061 | 0.247 | 0.246 | Cholinergic | 0.122 0.105 DBMET00027 0.246 0.03 DBMET03527 | DBMET03527 | |
| 0.04 | 0.228 | 0.287 | 5 Hydroxytryptamine 2B antagonist | 0.106 0.076 DBMET00027 0.287 0.015 DBMET03527 | DBMET03527 | |
| 0.051 | 0.24 | 0.108 | Nav1.4 sodium channel blocker | 0.1 0.075 DBMET03529 0.108 0.064 DBMET03531 | DBMET03531 | |
| 0.084 | 0.274 | 0.34 | Tumour necrosis factor alpha release inhibitor | 0.34 0.04 DBMET00028 | DBMET00028 | |
| 0.042 | 0.235 | 0.133 | Phosphodiesterase I inhibitor | 0.133 0.022 DBMET03527 | DBMET03527 | |
| 0.101 | 0.296 | 0.196 | Histone acetyltransferase inhibitor | 0.196 0.075 DBMET03527 0.16 0.125 DBMET03526 | DBMET03527 | |
| 0.016 | 0.211 | 0.068 | Phosphodiesterase 4C inhibitor | 0.068 0.028 DBMET00028 | DBMET00028 | |
| 0.015 | 0.214 | 0.053 | Glutamate (mGluR4) agonist | 0.053 0.01 DBMET03526 | DBMET03526 | |
| 0.019 | 0.219 | 0.143 | Phosphodiesterase 4D inhibitor | 0.143 0.021 DBMET00028 | DBMET00028 | |
| 0.029 | 0.229 | 0.087 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.087 0.015 DBMET03527 | DBMET03527 | |
| 0.018 | 0.225 | 0.046 | Adenosine uptake inhibitor | 0.046 0.005 DBMET03527 | DBMET03527 | |
| 0.005 | 0.212 | 0.042 | Urotensin II antagonist | 0.042 0.007 DBMET03527 | DBMET03527 | |
| 0.016 | 0.224 | 0.195 | Nicotinic receptor alpha7 subunit antagonist | 0.195 0.005 DBMET03527 | DBMET03527 | |
| 0.015 | 0.225 | 0.651 | 5 Hydroxytryptamine 1F antagonist | 0.651 0.003 DBMET03527 | DBMET03527 | |
| 0.12 | 0.331 | 0.227 | Nitric-oxide synthase stimulant | 0.227 0.052 DBMET03527 0.189 0.108 DBMET03526 | DBMET03527 | |
| 0.045 | 0.257 | 0.133 | Sodium channel (voltage-gated) blocker | 0.133 0.07 DBMET03527 | DBMET03527 | |
| 0.106 | 0.32 | 0.177 | Heat shock protein 70 antagonist | 0.177 0.013 DBMET03527 | DBMET03527 | |
| 0.108 | 0.323 | 0.305 | Immunosuppressant | 0.233 0.164 DBMET00026 0.22 0.176 DBMET03528 0.305 0.112 DBMET03530 | DBMET03530 | |
| 0.03 | 0.248 | 0.075 | Potassium channel (Tandem pore domain) blocker | 0.075 0.049 DBMET03527 | DBMET03527 | |
| 0.028 | 0.247 | 0.298 | Alpha 2 adrenoreceptor antagonist | 0.298 0.008 DBMET03527 | DBMET03527 | |
| 0.078 | 0.298 | 0.167 | Pregnane X receptor agonist | 0.167 0.029 DBMET03527 | DBMET03527 | |
| 0.046 | 0.271 | 0.12 | Sodium channel blocker | 0.12 0.084 DBMET03527 | DBMET03527 | |
| 0.032 | 0.262 | 0.094 | Phosphodiesterase 1C inhibitor | 0.094 0.012 DBMET03527 | DBMET03527 | |
| 0.023 | 0.253 | 0.044 | Benzodiazepine inverse agonist | 0.044 0.039 DBMET00028 | DBMET00028 | |
| 0.037 | 0.269 | 0.118 | Interleukin 1 beta converting enzyme inhibitor | 0.118 0.037 DBMET03527 | DBMET03527 | |
| 0.014 | 0.251 | 0.03 | GHS receptor antagonist | 0.03 0.028 DBMET03527 | DBMET03527 | |
| 0.011 | 0.25 | 0.093 | Poly(ADP-ribose) polymerase 1 inhibitor | 0.093 0.008 DBMET03527 | DBMET03527 | |
| 0.05 | 0.289 | 0.243 | NADPH oxidase inhibitor | 0.243 0.022 DBMET03527 | DBMET03527 | |
| 0.041 | 0.281 | 0.166 | Phosphodiesterase inhibitor | 0.166 0.048 DBMET00028 | DBMET00028 | |
| 0.013 | 0.253 | 0.602 | 5 Hydroxytryptamine 7 antagonist | 0.602 0.004 DBMET03527 | DBMET03527 | |
| 0.005 | 0.245 | 0.043 | Poly(ADP-ribose) polymerase 2 inhibitor | 0.043 0.01 DBMET03527 | DBMET03527 | |
| 0.007 | 0.247 | 0.101 | Myristoyl transferase inhibitor | 0.101 0.003 DBMET03527 | DBMET03527 | |
| 0.014 | 0.255 | 0.101 | Poly(ADP-ribose) polymerase inhibitor | 0.101 0.008 DBMET03527 | DBMET03527 | |
| 0.043 | 0.285 | 0.096 | mTOR complex 2 inhibitor | 0.096 0.039 DBMET03527 | DBMET03527 | |
| 0.011 | 0.257 | 0.169 | Phosphodiesterase 4A inhibitor | 0.169 0.009 DBMET00028 | DBMET00028 | |
| 0.014 | 0.262 | 0.255 | 5 Hydroxytryptamine 1B antagonist | 0.255 0.005 DBMET03527 | DBMET03527 | |
| 0.02 | 0.276 | 0.377 | 5 Hydroxytryptamine 1B agonist | 0.377 0.003 DBMET03527 | DBMET03527 | |
| 0.019 | 0.275 | 0.069 | Nav1.7 sodium channel blocker | 0.069 0.045 DBMET03527 | DBMET03527 | |
| 0.031 | 0.296 | 0.106 | Viral attachment inhibitor | 0.106 0.02 DBMET03527 | DBMET03527 | |
| 0.025 | 0.29 | 0.048 | Factor III inhibitor | 0.048 0.039 DBMET03526 | DBMET03526 | |
| 0.004 | 0.271 | 0.033 | Methionyl aminopeptidase 2 inhibitor | 0.033 0.012 DBMET03526 | DBMET03526 | |
| 0.029 | 0.305 | 0.086 | GABA A receptor agonist | 0.086 0.054 DBMET03527 | DBMET03527 | |
| 0.016 | 0.295 | 0.061 | Glutamate (mGluR group III) agonist | 0.061 0.018 DBMET03526 | DBMET03526 | |
| 0.003 | 0.284 | 0.094 | 5 Hydroxytryptamine 1D agonist | 0.094 0.004 DBMET03527 | DBMET03527 | |
| 0.02 | 0.304 | 0.055 | Fatty acid synthase inhibitor | 0.055 0.043 DBMET03527 | DBMET03527 | |
| 0.023 | 0.307 | 0.181 | Antihistaminic | 0.181 0.024 DBMET03527 | DBMET03527 | |
| 0.013 | 0.297 | 0.141 | Dopamine agonist | 0.141 0.016 DBMET03527 | DBMET03527 | |
| 0.005 | 0.29 | 0.023 | Alpha 2b adrenoreceptor agonist | 0.023 0.007 DBMET03527 | DBMET03527 | |
| 0.012 | 0.299 | 0.199 | Alpha 1 adrenoreceptor agonist | 0.199 0.006 DBMET03527 | DBMET03527 | |
| 0.004 | 0.292 | 0.08 | Nicotinic alpha3beta4 receptor agonist | 0.08 0.003 DBMET03527 | DBMET03527 | |
| 0.055 | 0.344 | 0.201 | Hexokinase inhibitor | 0.201 0.034 DBMET03526 | DBMET03526 | |
| 0.059 | 0.352 | 0.269 | Sigma receptor agonist | 0.269 0.045 DBMET03527 | DBMET03527 | |
| 0.003 | 0.297 | 0.025 | Alpha 2c adrenoreceptor agonist | 0.025 0.006 DBMET03527 | DBMET03527 | |
| 0.024 | 0.322 | 0.096 | Corticotropin releasing factor 2 receptor antagonist | 0.096 0.008 DBMET03527 | DBMET03527 | |
| 0.037 | 0.337 | 0.127 | Carbonic anhydrase III inhibitor | 0.086 0.081 DBMET03527 0.127 0.04 DBMET03526 | DBMET03526 | |
| 0.003 | 0.306 | 0.1 | Nicotinic alpha4 receptor agonist | 0.1 0.003 DBMET03527 | DBMET03527 | |
| 0.016 | 0.321 | 0.172 | Histamine antagonist | 0.172 0.024 DBMET03527 | DBMET03527 | |
| 0.014 | 0.319 | 0.083 | Myc inhibitor | 0.083 0.012 DBMET03527 | DBMET03527 | |
| 0.014 | 0.319 | 0.055 | Calcium channel T-type blocker | 0.055 0.046 DBMET03527 | DBMET03527 | |
| 0.041 | 0.348 | 0.157 | Nav1.1 sodium channel blocker | 0.157 0.03 DBMET03527 | DBMET03527 | |
| 0.021 | 0.328 | 0.083 | Secretase beta inhibitor | 0.083 0.033 DBMET03527 | DBMET03527 | |
| 0.006 | 0.314 | 0.418 | 5 Hydroxytryptamine 1 agonist | 0.418 0.005 DBMET03527 | DBMET03527 | |
| 0.008 | 0.317 | 0.049 | Glutamate (mGluR5) agonist | 0.049 0.026 DBMET03527 | DBMET03527 | |
| 0.02 | 0.332 | 0.046 | Factor IXa inhibitor | 0.046 0.044 DBMET00028 | DBMET00028 | |
| 0.084 | 0.398 | 0.163 | Catenin beta inhibitor | 0.163 0.078 DBMET03527 | DBMET03527 | |
| 0.002 | 0.316 | 0.024 | Cyclin T1 inhibitor | 0.024 0.008 DBMET03527 | DBMET03527 | |
| 0.01 | 0.327 | 0.047 | Retinoic acid alpha receptor agonist | 0.047 0.017 DBMET03526 | DBMET03526 | |
| 0.012 | 0.331 | 0.253 | Neuronal nicotinic receptor antagonist | 0.253 0.006 DBMET03527 | DBMET03527 | |
| 0.004 | 0.33 | 0.094 | Vascular adhesion protein 1 inhibitor | 0.094 0.004 DBMET03527 | DBMET03527 | |
| 0.024 | 0.35 | 0.1 | DNA intercalator | 0.1 0.074 DBMET03527 | DBMET03527 | |
| 0.002 | 0.328 | 0.029 | Imidazoline I2 receptor antagonist | 0.029 0.003 DBMET03527 | DBMET03527 | |
| 0.042 | 0.372 | 0.174 | Nav1.2 sodium channel blocker | 0.174 0.045 DBMET03527 | DBMET03527 | |
| 0.011 | 0.341 | 0.05 | Glutamate (mGluR1a) antagonist | 0.05 0.02 DBMET03527 | DBMET03527 | |
| 0.059 | 0.395 | 0.378 | 5 Hydroxytryptamine 1E antagonist | 0.378 0.006 DBMET03527 | DBMET03527 | |
| 0.02 | 0.355 | 0.099 | Glutamate (mGluR7) antagonist | 0.099 0.011 DBMET03527 | DBMET03527 | |
| 0.03 | 0.369 | 0.178 | Nav1.6 sodium channel blocker | 0.178 0.029 DBMET03527 | DBMET03527 | |
| 0.01 | 0.351 | 0.083 | Dihydroorotase inhibitor | 0.083 0.008 DBMET03526 | DBMET03526 | |
| 0.05 | 0.391 | 0.275 | DNA methylase inhibitor | 0.275 0.036 DBMET03527 | DBMET03527 | |
| 0.005 | 0.347 | 0.038 | Dopamine D3 agonist | 0.038 0.029 DBMET03527 | DBMET03527 | |
| 0.024 | 0.366 | 0.097 | Alpha 1b adrenoreceptor agonist | 0.097 0.005 DBMET03527 | DBMET03527 | |
| 0.003 | 0.346 | 0.025 | Alpha 2a adrenoreceptor agonist | 0.025 0.006 DBMET03527 | DBMET03527 | |
| 0.01 | 0.354 | 0.066 | NMDA 2B receptor antagonist | 0.066 0.027 DBMET03525 | DBMET03525 | |
| 0.013 | 0.359 | 0.222 | Purinergic P2X2 antagonist | 0.222 0.004 DBMET00026 | DBMET00026 | |
| 0.035 | 0.381 | 0.073 | Prolactin release inhibitor | 0.073 0.019 DBMET03527 | DBMET03527 | |
| 0.015 | 0.362 | 0.105 | CYP2A6 inhibitor | 0.105 0.033 DBMET03527 | DBMET03527 | |
| 0.004 | 0.352 | 0.043 | Sigma receptor antagonist | 0.043 0.039 DBMET03527 | DBMET03527 | |
| 0.038 | 0.39 | 0.158 | Acetylcholine release stimulant | 0.158 0.012 DBMET03527 | DBMET03527 | |
| 0.022 | 0.377 | 0.065 | Ca(v)3.2 blocker | 0.065 0.029 DBMET03527 | DBMET03527 | |
| 0.009 | 0.366 | 0.119 | Dihydroorotate dehydrogenase inhibitor | 0.119 0.008 DBMET03526 | DBMET03526 | |
| 0.004 | 0.362 | 0.069 | Imidazoline I1 receptor antagonist | 0.069 0.003 DBMET03527 | DBMET03527 | |
| 0.008 | 0.367 | 0.166 | 5 Hydroxytryptamine 6 antagonist | 0.166 0.005 DBMET03527 | DBMET03527 | |
| 0.005 | 0.367 | 0.043 | Histamine H3 receptor agonist | 0.043 0.013 DBMET03527 | DBMET03527 | |
| 0.007 | 0.37 | 0.045 | Nicotinic receptor beta4 subunit antagonist | 0.045 0.018 DBMET03527 | DBMET03527 | |
| 0.02 | 0.386 | 0.059 | Glucosylceramidase inhibitor | 0.059 0.032 DBMET03527 | DBMET03527 | |
| 0.003 | 0.371 | 0.053 | Histamine H3 receptor antagonist | 0.053 0.024 DBMET03527 | DBMET03527 | |
| 0.005 | 0.374 | 0.07 | Dopamine D4 antagonist | 0.07 0.037 DBMET03527 | DBMET03527 | |
| 0.006 | 0.382 | 0.043 | Alpha 1a adrenoreceptor agonist | 0.043 0.006 DBMET03527 | DBMET03527 | |
| 0.006 | 0.389 | 0.023 | Factor XIII inhibitor | 0.023 0.009 DBMET03527 | DBMET03527 | |
| 0.004 | 0.389 | 0.048 | Dopamine D2 agonist | 0.048 0.028 DBMET03527 | DBMET03527 | |
| 0.013 | 0.4 | 0.334 | 5 Hydroxytryptamine antagonist | 0.334 0.015 DBMET03527 | DBMET03527 | |
| 0.008 | 0.394 | 0.058 | Delayed rectifier potassium channel blocker | 0.058 0.008 DBMET03527 | DBMET03527 | |
| 0.009 | 0.396 | 0.25 | 5 Hydroxytryptamine 2C antagonist | 0.25 0.012 DBMET03527 | DBMET03527 | |
| 0.004 | 0.391 | 0.037 | Dipeptidyl peptidase I inhibitor | 0.037 0.015 DBMET03527 | DBMET03527 | |
| 0.015 | 0.404 | 0.105 | M17 leucyl aminopeptidase inhibitor | 0.105 0.094 DBMET03526 | DBMET03526 | |
| 0.026 | 0.415 | 0.123 | HIV-1 integrase (Overall Integration) inhibitor | 0.123 0.038 DBMET03527 | DBMET03527 | |
| 0.005 | 0.393 | 0.212 | 5 Hydroxytryptamine 1A agonist | 0.212 0.008 DBMET03527 | DBMET03527 | |
| 0.046 | 0.438 | 0.21 | Antipruritic | 0.21 0.042 DBMET03527 | DBMET03527 | |
| 0.025 | 0.422 | 0.27 | Cytidine deaminase inhibitor | 0.27 0.024 DBMET03527 | DBMET03527 | |
| 0.009 | 0.408 | 0.148 | Histamine H1 receptor antagonist | 0.148 0.025 DBMET03527 | DBMET03527 | |
| 0.044 | 0.443 | 0.105 | CC chemokine 5 receptor agonist | 0.105 0.017 DBMET03527 | DBMET03527 | |
| 0.023 | 0.423 | 0.32 | 5 Hydroxytryptamine 3A agonist | 0.32 0.003 DBMET03527 | DBMET03527 | |
| 0.049 | 0.449 | 0.168 | 3C-like protease (Human coronavirus) inhibitor | 0.168 0.076 DBMET03527 | DBMET03527 | |
| 0.008 | 0.409 | 0.152 | Acetylcholine M5 receptor agonist | 0.152 0.005 DBMET03527 | DBMET03527 | |
| 0.005 | 0.408 | 0.032 | Epoxide hydrolase 1 inhibitor | 0.032 0.02 DBMET03527 | DBMET03527 | |
| 0.018 | 0.422 | 0.154 | Histamine N-methyltransferase inhibitor | 0.154 0.013 DBMET03527 | DBMET03527 | |
| 0.003 | 0.409 | 0.087 | Nicotinic alpha4beta2 receptor agonist | 0.087 0.003 DBMET03527 | DBMET03527 | |
| 0.012 | 0.42 | 0.041 | Thymidine kinase inhibitor | 0.041 0.029 DBMET03527 | DBMET03527 | |
| 0.079 | 0.488 | 0.298 | Analgesic | 0.298 0.143 DBMET03527 | DBMET03527 | |
| 0.011 | 0.421 | 0.274 | Acetylcholine nicotinic antagonist | 0.274 0.008 DBMET03527 | DBMET03527 | |
| 0.061 | 0.471 | 0.196 | Neuropeptide Y2 antagonist | 0.196 0.126 DBMET03527 | DBMET03527 | |
| 0.003 | 0.413 | 0.041 | Endothelial nitric-oxide synthase inhibitor | 0.041 0.013 DBMET03527 | DBMET03527 | |
| 0.004 | 0.415 | 0.034 | Carnitine palmitoyltransferase 1 inhibitor | 0.034 0.024 DBMET03527 | DBMET03527 | |
| 0.005 | 0.417 | 0.05 | Glutamate (mGluR group I) agonist | 0.05 0.031 DBMET03527 | DBMET03527 | |
| 0.002 | 0.415 | 0.022 | CXC chemokine 4 receptor agonist | 0.022 0.005 DBMET03527 | DBMET03527 | |
| 0.003 | 0.417 | 0.104 | Acetylcholine M4 receptor agonist | 0.104 0.004 DBMET03527 | DBMET03527 | |
| 0.006 | 0.422 | 0.205 | 5 Hydroxytryptamine 1 antagonist | 0.205 0.016 DBMET03527 | DBMET03527 | |
| 0.023 | 0.439 | 0.132 | GABA receptor agonist | 0.132 0.047 DBMET03527 | DBMET03527 | |
| 0.042 | 0.459 | 0.335 | Interleukin agonist | 0.335 0.033 DBMET03527 | DBMET03527 | |
| 0.029 | 0.446 | 0.332 | Acetylcholine M1 receptor antagonist | 0.332 0.01 DBMET03527 | DBMET03527 | |
| 0.001 | 0.42 | 0.014 | Immunosuppressant Cyclosporine-like | 0.014 0.005 DBMET03530 | DBMET03530 | |
| 0.013 | 0.433 | 0.1 | Dopamine beta hydroxylase inhibitor | 0.1 0.004 DBMET03527 | DBMET03527 | |
| 0.012 | 0.434 | 0.123 | 5 Hydroxytryptamine 7 agonist | 0.123 0.005 DBMET03527 | DBMET03527 | |
| 0.02 | 0.442 | 0.353 | Ferrochelatase inhibitor | 0.353 0.005 DBMET03527 0.111 0.061 DBMET03526 | DBMET03527 | |
| 0.012 | 0.437 | 0.293 | 5 Hydroxytryptamine 2 antagonist | 0.293 0.017 DBMET03527 | DBMET03527 | |
| 0.008 | 0.437 | 0.064 | Histamine H2 receptor agonist | 0.064 0.013 DBMET03527 | DBMET03527 | |
| 0.004 | 0.434 | 0.033 | Carnitine palmitoyltransferase inhibitor | 0.033 0.025 DBMET03527 | DBMET03527 | |
| 0.062 | 0.494 | 0.242 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.242 0.046 DBMET03527 | DBMET03527 | |
| 0.018 | 0.45 | 0.058 | Purinergic P2X1 antagonist | 0.058 0.046 DBMET03526 | DBMET03526 | |
| 0.007 | 0.441 | 0.05 | Glycine transporter 2 inhibitor | 0.05 0.03 DBMET03527 | DBMET03527 | |
| 0.005 | 0.44 | 0.148 | Acetylcholine M2 receptor antagonist | 0.148 0.011 DBMET03527 | DBMET03527 | |
| 0.102 | 0.537 | 0.494 | Caspase 9 stimulant | 0.494 0.062 DBMET03527 | DBMET03527 | |
| 0.005 | 0.44 | 0.025 | Geranylgeranyltransferase inhibitor | 0.025 0.012 DBMET03527 | DBMET03527 | |
| 0.018 | 0.456 | 0.093 | Myeloperoxidase inhibitor | 0.093 0.045 DBMET03527 | DBMET03527 | |
| 0.011 | 0.451 | 0.068 | Sphingosine kinase 2 inhibitor | 0.068 0.023 DBMET03527 | DBMET03527 | |
| 0.005 | 0.447 | 0.107 | Alpha 1d adrenoreceptor agonist | 0.107 0.003 DBMET03527 | DBMET03527 | |
| 0.008 | 0.454 | 0.061 | Ceramide glucosyltransferase inhibitor | 0.061 0.004 DBMET03527 | DBMET03527 | |
| 0.012 | 0.46 | 0.098 | Somatostatin 4 agonist | 0.098 0.007 DBMET03527 | DBMET03527 | |
| 0.007 | 0.457 | 0.042 | Sphingosine kinase 1 inhibitor | 0.042 0.027 DBMET03527 | DBMET03527 | |
| 0.003 | 0.454 | 0.194 | Acetylcholine M1 receptor agonist | 0.194 0.005 DBMET03527 | DBMET03527 | |
| 0.043 | 0.497 | 0.288 | DNA damaging | 0.288 0.062 DBMET03527 | DBMET03527 | |
| 0.006 | 0.462 | 0.061 | Nerve growth factor antagonist | 0.061 0.009 DBMET03527 | DBMET03527 | |
| 0.063 | 0.519 | 0.157 | Neurotensin receptor agonist | 0.157 0.086 DBMET03527 | DBMET03527 | |
| 0.025 | 0.482 | 0.174 | Protein kinase stimulant | 0.174 0.053 DBMET03527 | DBMET03527 | |
| 0.053 | 0.512 | 0.148 | Sphingosine 1-phosphate receptor 5 antagonist | 0.148 0.064 DBMET03527 | DBMET03527 | |
| 0.005 | 0.466 | 0.217 | Acetylcholine muscarinic agonist | 0.217 0.005 DBMET03527 | DBMET03527 | |
| 0.008 | 0.468 | 0.081 | Acetylcholine M2 receptor agonist | 0.081 0.013 DBMET03527 | DBMET03527 | |
| 0.021 | 0.483 | 0.293 | Acetylcholine antagonist | 0.293 0.014 DBMET03527 | DBMET03527 | |
| 0.032 | 0.495 | 0.287 | DNA methyltransferase I inhibitor | 0.287 0.031 DBMET03527 | DBMET03527 | |
| 0.026 | 0.489 | 0.107 | MAP kinase kinase 7 inhibitor | 0.107 0.008 DBMET03527 | DBMET03527 | |
| 0.024 | 0.49 | 0.145 | Electrolyte absorption antagonist | 0.145 0.021 DBMET03527 0.1 0.057 DBMET03526 | DBMET03527 | |
| 0.007 | 0.473 | 0.105 | Dopamine D3 antagonist | 0.105 0.023 DBMET03527 | DBMET03527 | |
| 0.004 | 0.471 | 0.051 | Acid ceramidase inhibitor | 0.051 0.003 DBMET03527 | DBMET03527 | |
| 0.017 | 0.484 | 0.148 | Cystathionine beta-synthase inhibitor | 0.148 0.041 DBMET03527 | DBMET03527 | |
| 0.021 | 0.49 | 0.298 | Cholinergic antagonist | 0.298 0.014 DBMET03527 | DBMET03527 | |
| 0.049 | 0.521 | 0.48 | Superoxide dismutase inhibitor | 0.48 0.015 DBMET03527 0.177 0.146 DBMET03526 | DBMET03527 | |
| 0.041 | 0.514 | 0.409 | Cyclic AMP phosphodiesterase inhibitor | 0.409 0.015 DBMET03527 | DBMET03527 | |
| 0.01 | 0.49 | 0.235 | Alpha adrenoreceptor antagonist | 0.235 0.022 DBMET03527 | DBMET03527 | |
| 0.011 | 0.491 | 0.076 | Carbonic anhydrase stimulant | 0.076 0.028 DBMET03527 | DBMET03527 | |
| 0.003 | 0.483 | 0.053 | Geranyltranstransferase inhibitor | 0.053 0.019 DBMET03527 | DBMET03527 | |
| 0.004 | 0.484 | 0.044 | Purinergic P2Y antagonist | 0.044 0.032 DBMET03527 | DBMET03527 | |
| 0.003 | 0.484 | 0.04 | Diamine oxidase inhibitor | 0.04 0.024 DBMET03527 | DBMET03527 | |
| 0.013 | 0.496 | 0.483 | Adrenaline antagonist | 0.483 0.005 DBMET03527 | DBMET03527 | |
| 0.004 | 0.487 | 0.061 | 5 Hydroxytryptamine 6 agonist | 0.061 0.004 DBMET03527 | DBMET03527 | |
| 0.01 | 0.493 | 0.079 | Analgesic, opioid | 0.079 0.049 DBMET03527 | DBMET03527 | |
| 0.032 | 0.515 | 0.096 | D-Ala-D-Ala ligase inhibitor | 0.096 0.035 DBMET03527 | DBMET03527 | |
| 0.005 | 0.49 | 0.703 | 5 Hydroxytryptamine agonist | 0.703 0.004 DBMET03527 | DBMET03527 | |
| 0.024 | 0.51 | 0.117 | Vanilloid 4 agonist | 0.117 0.008 DBMET03527 | DBMET03527 | |
| 0.006 | 0.494 | 0.084 | Benzodiazepine agonist | 0.084 0.036 DBMET03527 | DBMET03527 | |
| 0.013 | 0.501 | 0.486 | Antiadrenergic | 0.486 0.005 DBMET03527 | DBMET03527 | |
| 0.023 | 0.511 | 0.118 | Calcium channel N-type blocker | 0.118 0.066 DBMET03527 | DBMET03527 | |
| 0.025 | 0.514 | 0.121 | Alpha 2d adrenoreceptor antagonist | 0.121 0.023 DBMET03527 | DBMET03527 | |
| 0.006 | 0.495 | 0.101 | 5 Hydroxytryptamine 4 antagonist | 0.101 0.006 DBMET03527 | DBMET03527 | |
| 0.004 | 0.494 | 0.028 | Glutaminyl-peptide cyclotransferase inhibitor | 0.028 0.008 DBMET03527 | DBMET03527 | |
| 0.01 | 0.502 | 0.047 | Cytokine production stimulant | 0.047 0.038 DBMET03527 | DBMET03527 | |
| 0.023 | 0.516 | 0.089 | Bile acid receptor antagonist | 0.089 0.077 DBMET03527 | DBMET03527 | |
| 0.008 | 0.502 | 0.062 | Sphingosine kinase inhibitor | 0.062 0.036 DBMET03527 | DBMET03527 | |
| 0.006 | 0.5 | 0.04 | Factor XIIIa inhibitor | 0.04 0.024 DBMET03527 | DBMET03527 | |
| 0.009 | 0.503 | 0.048 | Estrogen-related receptor beta antagonist | 0.048 0.006 DBMET03527 | DBMET03527 | |
| 0.014 | 0.513 | 0.135 | Diuretic | 0.135 0.09 DBMET03527 | DBMET03527 | |
| 0.038 | 0.538 | 0.161 | ATPase inhibitor | 0.161 0.084 DBMET03527 | DBMET03527 | |
| 0.01 | 0.514 | 0.08 | S-adenosyl-L-methionine decarboxylase inhibitor | 0.08 0.037 DBMET03527 | DBMET03527 | |
| 0.005 | 0.509 | 0.046 | Factor XIa inhibitor | 0.046 0.022 DBMET00028 | DBMET00028 | |
| 0.007 | 0.512 | 0.163 | Acetylcholine M5 receptor antagonist | 0.163 0.006 DBMET03527 | DBMET03527 | |
| 0.064 | 0.57 | 0.62 | GABA C receptor rho-3 antagonist | 0.62 0.005 DBMET03527 | DBMET03527 | |
| 0.006 | 0.513 | 0.108 | Nicotinic receptor alpha3 subunit antagonist | 0.108 0.009 DBMET03527 | DBMET03527 | |
| 0.001 | 0.51 | 0.01 | Calcineurin inhibitor | 0.01 0.009 DBMET03530 | DBMET03530 | |
| 0.022 | 0.531 | 0.054 | Immunoglobulin Fc receptor antagonist | 0.054 0.041 DBMET03527 | DBMET03527 | |
| 0.003 | 0.513 | 0.022 | Estrogen-related receptor gamma agonist | 0.022 0.008 DBMET03527 | DBMET03527 | |
| 0.022 | 0.537 | 0.177 | Nav1.3 sodium channel blocker | 0.177 0.033 DBMET03527 | DBMET03527 | |
| 0.004 | 0.52 | 0.192 | Dopamine D5 antagonist | 0.192 0.005 DBMET03527 | DBMET03527 | |
| 0.012 | 0.529 | 0.042 | CF transmembrane conductance regulator antagonist | 0.042 0.022 DBMET03527 | DBMET03527 | |
| 0.014 | 0.532 | 0.101 | Ryanodine receptor antagonist | 0.101 0.004 DBMET03527 | DBMET03527 | |
| 0.004 | 0.522 | 0.159 | 5 Hydroxytryptamine 1A antagonist | 0.159 0.019 DBMET03527 | DBMET03527 | |
| 0.01 | 0.528 | 0.204 | Acetylcholine M4 receptor antagonist | 0.204 0.006 DBMET03527 | DBMET03527 | |
| 0.003 | 0.524 | 0.038 | Methionyl aminopeptidase 1 inhibitor | 0.038 0.014 DBMET03527 | DBMET03527 | |
| 0.007 | 0.531 | 0.06 | Estrogen-related receptor gamma antagonist | 0.06 0.003 DBMET03527 | DBMET03527 | |
| 0.003 | 0.531 | 0.027 | 5 Hydroxytryptamine 4 agonist | 0.027 0.01 DBMET03527 | DBMET03527 | |
| 0.005 | 0.536 | 0.17 | Alpha 1 adrenoreceptor antagonist | 0.17 0.026 DBMET03527 | DBMET03527 | |
| 0.039 | 0.571 | 0.198 | Neurotrophic factor enhancer | 0.198 0.078 DBMET03527 | DBMET03527 | |
| 0.005 | 0.538 | 0.07 | Histamine H1 receptor agonist | 0.07 0.005 DBMET03527 | DBMET03527 | |
| 0.038 | 0.571 | 0.162 | Glutamate release inhibitor | 0.162 0.008 DBMET03527 | DBMET03527 | |
| 0.004 | 0.541 | 0.166 | Alpha 1b adrenoreceptor antagonist | 0.166 0.019 DBMET03527 | DBMET03527 | |
| 0.014 | 0.555 | 0.249 | Acetylcholine muscarinic antagonist | 0.249 0.015 DBMET03527 | DBMET03527 | |
| 0.007 | 0.549 | 0.181 | Dopamine transporter inhibitor | 0.181 0.005 DBMET03527 | DBMET03527 | |
| 0.015 | 0.558 | 0.095 | Alpha 1L adrenoreceptor agonist | 0.095 0.003 DBMET03527 | DBMET03527 | |
| 0.004 | 0.554 | 0.136 | Alpha 1a adrenoreceptor antagonist | 0.136 0.026 DBMET03527 | DBMET03527 | |
| 0.016 | 0.567 | 0.081 | Keratolytic | 0.081 0.047 DBMET03526 | DBMET03526 | |
| 0.004 | 0.556 | 0.244 | 5 Hydroxytryptamine 2A antagonist | 0.244 0.015 DBMET03527 | DBMET03527 | |
| 0.02 | 0.58 | 0.123 | Antibacterial (Helicobacter pylori) | 0.123 0.077 DBMET03527 | DBMET03527 | |
| 0.016 | 0.576 | 0.177 | Acetylcholine M3 receptor agonist | 0.177 0.008 DBMET03527 | DBMET03527 | |
| 0.005 | 0.566 | 0.522 | 5 Hydroxytryptamine uptake inhibitor | 0.522 0.004 DBMET03527 | DBMET03527 | |
| 0.006 | 0.569 | 0.077 | Mannitol-1-phosphate 5-dehydrogenase inhibitor | 0.077 0.022 DBMET03527 | DBMET03527 | |
| 0.087 | 0.65 | 0.279 | 5 Hydroxytryptamine 3E antagonist | 0.279 0.008 DBMET03527 | DBMET03527 | |
| 0.036 | 0.601 | 0.174 | DNA repair enzyme inhibitor | 0.174 0.016 DBMET03527 | DBMET03527 | |
| 0.007 | 0.573 | 0.027 | Complement factor 1s inhibitor | 0.027 0.012 DBMET03527 | DBMET03527 | |
| 0.007 | 0.578 | 0.153 | Anesthetic local | 0.153 0.047 DBMET03527 | DBMET03527 | |
| 0.004 | 0.575 | 0.15 | Acetylcholine M3 receptor antagonist | 0.15 0.011 DBMET03527 | DBMET03527 | |
| 0.005 | 0.577 | 0.022 | ICAM 1 antagonist | 0.022 0.019 DBMET03527 | DBMET03527 | |
| 0.006 | 0.579 | 0.037 | Integrin alpha2 antagonist | 0.037 0.025 DBMET03527 | DBMET03527 | |
| 0.01 | 0.586 | 0.051 | Glutamate (mGluR group III) antagonist | 0.051 0.02 DBMET03527 | DBMET03527 | |
| 0.007 | 0.585 | 0.025 | Thymidine kinase (Herpes simplex virus 1) inhibitor | 0.025 0.024 DBMET03527 | DBMET03527 | |
| 0.005 | 0.583 | 0.137 | Dopamine antagonist | 0.137 0.028 DBMET03527 | DBMET03527 | |
| 0.006 | 0.589 | 0.084 | MAO A inhibitor | 0.084 0.076 DBMET03527 | DBMET03527 | |
| 0.013 | 0.597 | 0.058 | Topoisomerase II beta inhibitor | 0.058 0.024 DBMET03527 | DBMET03527 | |
| 0.004 | 0.589 | 0.088 | NMDA 2C receptor antagonist | 0.088 0.021 DBMET03527 | DBMET03527 | |
| 0.014 | 0.603 | 0.103 | Beta glucuronidase inhibitor | 0.103 0.065 DBMET03527 | DBMET03527 | |
| 0.009 | 0.599 | 0.054 | Purinergic P2X4 antagonist | 0.054 0.02 DBMET03527 | DBMET03527 | |
| 0.002 | 0.597 | 0.032 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | 0.032 0.016 DBMET03527 | DBMET03527 | |
| 0.011 | 0.607 | 0.093 | Interferon inducer | 0.093 0.016 DBMET03527 | DBMET03527 | |
| 0.024 | 0.622 | 0.236 | Peroxidase inhibitor | 0.236 0.05 DBMET03527 | DBMET03527 | |
| 0.004 | 0.603 | 0.031 | Thymidine phosphorylase inhibitor | 0.031 0.011 DBMET03527 | DBMET03527 | |
| 0.001 | 0.601 | 0.016 | NMDA receptor phencyclidine site antagonist | 0.016 0.01 DBMET03527 | DBMET03527 | |
| 0.002 | 0.602 | 0.035 | Lysine carboxypeptidase inhibitor | 0.035 0.012 DBMET03527 | DBMET03527 | |
| 0.005 | 0.607 | 0.186 | Dopamine D1 antagonist | 0.186 0.011 DBMET03527 | DBMET03527 | |
| 0.003 | 0.607 | 0.118 | Dopamine D2 antagonist | 0.118 0.028 DBMET03527 | DBMET03527 | |
| 0.02 | 0.629 | 0.152 | Neuropeptide Y1 antagonist | 0.152 0.063 DBMET03527 | DBMET03527 | |
| 0.004 | 0.615 | 0.043 | Substance P antagonist | 0.043 0.023 DBMET03527 | DBMET03527 | |
| 0.006 | 0.618 | 0.138 | Alkylator | 0.138 0.054 DBMET03527 | DBMET03527 | |
| 0.003 | 0.615 | 0.059 | Glycine transporter inhibitor | 0.059 0.025 DBMET03527 | DBMET03527 | |
| 0.01 | 0.627 | 0.04 | DNA gyrase subunit A inhibitor | 0.04 0.036 DBMET03527 | DBMET03527 | |
| 0.006 | 0.623 | 0.078 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.078 0.053 DBMET03527 | DBMET03527 | |
| 0.01 | 0.631 | 0.06 | GHS receptor agonist | 0.06 0.013 DBMET03527 | DBMET03527 | |
| 0.013 | 0.634 | 0.12 | Nicotinic alpha3beta2 receptor antagonist | 0.12 0.005 DBMET03527 | DBMET03527 | |
| 0.019 | 0.642 | 0.143 | Thiol protease inhibitor | 0.143 0.076 DBMET03527 | DBMET03527 | |
| 0.004 | 0.629 | 0.051 | Neurokinin antagonist | 0.051 0.033 DBMET03527 | DBMET03527 | |
| 0.003 | 0.63 | 0.031 | LFA antagonist | 0.031 0.014 DBMET03527 | DBMET03527 | |
| 0.006 | 0.635 | 0.331 | Adrenaline uptake inhibitor | 0.331 0.004 DBMET03527 | DBMET03527 | |
| 0.003 | 0.632 | 0.118 | Alpha 1d adrenoreceptor antagonist | 0.118 0.019 DBMET03527 | DBMET03527 | |
| 0.055 | 0.686 | 0.185 | Ca2+-transporting ATPase inhibitor | 0.185 0.005 DBMET03527 | DBMET03527 | |
| 0.007 | 0.639 | 0.083 | Adenylate cyclase 1 inhibitor | 0.083 0.007 DBMET03527 | DBMET03527 | |
| 0.023 | 0.658 | 0.267 | GABA C receptor rho-2 antagonist | 0.267 0.009 DBMET03527 | DBMET03527 | |
| 0.018 | 0.652 | 0.088 | Granulocyte macrophage colony stimulating factor agonist | 0.088 0.056 DBMET03527 | DBMET03527 | |
| 0.004 | 0.639 | 0.045 | Neurokinin 1 antagonist | 0.045 0.023 DBMET03527 | DBMET03527 | |
| 0.008 | 0.648 | 0.143 | Nitric-oxide synthase inhibitor | 0.143 0.026 DBMET03527 | DBMET03527 | |
| 0.008 | 0.654 | 0.111 | Interferon agonist | 0.111 0.021 DBMET03527 | DBMET03527 | |
| 0.004 | 0.651 | 0.052 | Cathepsin L inhibitor | 0.052 0.048 DBMET03527 | DBMET03527 | |
| 0.006 | 0.655 | 0.075 | Dipeptidyl peptidase inhibitor | 0.075 0.016 DBMET03527 | DBMET03527 | |
| 0.01 | 0.659 | 0.056 | CC chemokine 4 receptor antagonist | 0.056 0.019 DBMET03527 | DBMET03527 | |
| 0.005 | 0.655 | 0.105 | Porphobilinogen synthase inhibitor | 0.105 0.034 DBMET03527 | DBMET03527 | |
| 0.005 | 0.662 | 0.055 | Dipeptidyl peptidase IV inhibitor | 0.055 0.015 DBMET03527 | DBMET03527 | |
| 0.01 | 0.668 | 0.045 | Glutamate (mGluR4) antagonist | 0.045 0.027 DBMET03527 | DBMET03527 | |
| 0.001 | 0.659 | 0.037 | Kainate receptor 1 antagonist | 0.037 0.008 DBMET03527 | DBMET03527 | |
| 0.031 | 0.69 | 0.277 | RNA-directed DNA polymerase inhibitor | 0.277 0.037 DBMET03527 | DBMET03527 | |
| 0.006 | 0.667 | 0.084 | Epithelial sodium channel blocker | 0.084 0.011 DBMET03527 | DBMET03527 | |
| 0.034 | 0.697 | 0.266 | Insulysin inhibitor | 0.266 0.082 DBMET03527 | DBMET03527 | |
| 0.002 | 0.666 | 0.064 | Kainate receptor antagonist | 0.064 0.014 DBMET03527 | DBMET03527 | |
| 0.009 | 0.675 | 0.142 | Sphingosine 1-phosphate receptor 2 antagonist | 0.142 0.052 DBMET03527 | DBMET03527 | |
| 0.005 | 0.672 | 0.105 | Adrenaline agonist | 0.105 0.033 DBMET03527 | DBMET03527 | |
| 0.007 | 0.676 | 0.188 | Calcium antagonist | 0.188 0.015 DBMET03527 | DBMET03527 | |
| 0.006 | 0.675 | 0.05 | Adenosine deaminase inhibitor | 0.05 0.03 DBMET03527 | DBMET03527 | |
| 0.015 | 0.688 | 0.122 | Triose-phosphate isomerase inhibitor | 0.122 0.031 DBMET03527 | DBMET03527 | |
| 0.008 | 0.681 | 0.067 | Protease 3C (Human rhinovirus) inhibitor | 0.067 0.041 DBMET03527 | DBMET03527 | |
| 0.002 | 0.676 | 0.036 | Phosphoglycerate kinase inhibitor | 0.036 0.023 DBMET03527 | DBMET03527 | |
| 0.002 | 0.678 | 0.044 | Guanylate cyclase inhibitor | 0.044 0.027 DBMET03527 | DBMET03527 | |
| 0.022 | 0.7 | 0.093 | Glutamate (mGluR7) agonist | 0.093 0.075 DBMET03527 | DBMET03527 | |
| 0.013 | 0.693 | 0.093 | MDM2 inhibitor | 0.093 0.01 DBMET03527 | DBMET03527 | |
| 0.003 | 0.683 | 0.06 | NMDA receptor glycine site agonist | 0.06 0.045 DBMET03527 | DBMET03527 | |
| 0.065 | 0.746 | 0.522 | 5 Hydroxytryptamine uptake stimulant | 0.522 0.004 DBMET03527 | DBMET03527 | |
| 0.004 | 0.688 | 0.097 | Biliverdin reductase inhibitor | 0.097 0.019 DBMET03527 | DBMET03527 | |
| 0.007 | 0.696 | 0.329 | Anesthetic general | 0.329 0.027 DBMET03527 | DBMET03527 | |
| 0.004 | 0.693 | 0.047 | Toll-Like receptor 2 agonist | 0.047 0.025 DBMET03527 | DBMET03527 | |
| 0.005 | 0.702 | 0.052 | Aconitate hydratase inhibitor | 0.052 0.035 DBMET03527 | DBMET03527 | |
| 0.007 | 0.709 | 0.057 | Glucose-6-phosphate isomerase inhibitor | 0.057 0.021 DBMET03527 | DBMET03527 | |
| 0.007 | 0.71 | 0.259 | Anticonvulsant | 0.259 0.054 DBMET03527 | DBMET03527 | |
| 0.003 | 0.71 | 0.157 | 5 Hydroxytryptamine 2A agonist | 0.157 0.005 DBMET03527 | DBMET03527 | |
| 0.023 | 0.732 | 0.1 | Estrogen-related receptor beta agonist | 0.1 0.025 DBMET03527 | DBMET03527 | |
| 0.021 | 0.731 | 0.254 | Cholesterol antagonist | 0.254 0.122 DBMET03527 | DBMET03527 | |
| 0.003 | 0.717 | 0.048 | GABA receptor antagonist | 0.048 0.047 DBMET03527 | DBMET03527 | |
| 0.027 | 0.742 | 0.509 | Vasodilator, peripheral | 0.509 0.026 DBMET03527 | DBMET03527 | |
| 0.007 | 0.724 | 0.06 | Pregnane X receptor antagonist | 0.06 0.031 DBMET03527 | DBMET03527 | |
| 0.017 | 0.735 | 0.113 | Lanosterol 14 alpha demethylase inhibitor | 0.113 0.038 DBMET03527 | DBMET03527 | |
| 0.055 | 0.778 | 0.206 | Interleukin 2 agonist | 0.202 0.186 DBMET03527 0.206 0.178 DBMET03530 | DBMET03530 | |
| 0.012 | 0.735 | 0.16 | Adenylate cyclase inhibitor | 0.16 0.039 DBMET03527 | DBMET03527 | |
| 0.005 | 0.729 | 0.426 | Psychostimulant | 0.426 0.019 DBMET03527 | DBMET03527 | |
| 0.001 | 0.726 | 0.012 | Integrin beta2 antagonist | 0.012 0.009 DBMET03527 | DBMET03527 | |
| 0.009 | 0.737 | 0.245 | GABA C receptor rho-1 antagonist | 0.245 0.004 DBMET03527 | DBMET03527 | |
| 0.004 | 0.734 | 0.095 | Histidine decarboxylase inhibitor | 0.095 0.034 DBMET03527 | DBMET03527 | |
| 0.007 | 0.739 | 0.115 | Phospholipase D inhibitor | 0.115 0.008 DBMET03527 | DBMET03527 | |
| 0.024 | 0.757 | 0.379 | Vasodilator, coronary | 0.379 0.043 DBMET03527 | DBMET03527 | |
| 0.005 | 0.739 | 0.057 | NMDA receptor agonist | 0.057 0.053 DBMET03527 | DBMET03527 | |
| 0.004 | 0.74 | 0.176 | Dopamine uptake inhibitor | 0.176 0.008 DBMET03527 | DBMET03527 | |
| 0.008 | 0.745 | 0.185 | Creatine kinase inhibitor | 0.185 0.013 DBMET03527 | DBMET03527 | |
| 0.004 | 0.741 | 0.113 | Inducible nitric-oxide synthase inhibitor | 0.113 0.028 DBMET03527 | DBMET03527 | |
| 0.002 | 0.74 | 0.071 | Kainate receptor 2 antagonist | 0.071 0.009 DBMET03527 | DBMET03527 | |
| 0.003 | 0.745 | 0.453 | 5 Hydroxytryptamine 2C agonist | 0.453 0.003 DBMET03527 | DBMET03527 | |
| 0.002 | 0.748 | 0.154 | 5 Hydroxytryptamine 2 agonist | 0.154 0.005 DBMET03527 | DBMET03527 | |
| 0.017 | 0.766 | 0.127 | Photosensitizer | 0.127 0.049 DBMET03527 | DBMET03527 | |
| 0.009 | 0.758 | 0.385 | Alpha-N-acetylglucosaminidase inhibitor | 0.385 0.01 DBMET03527 | DBMET03527 | |
| 0.002 | 0.754 | 0.033 | NMDA receptor subunit 3A antagonist | 0.033 0.031 DBMET03527 | DBMET03527 | |
| 0.011 | 0.763 | 0.116 | Sphingomyelinase inhibitor | 0.116 0.044 DBMET03527 | DBMET03527 | |
| 0.002 | 0.755 | 0.077 | Alcohol oxidase inhibitor | 0.077 0.026 DBMET03527 | DBMET03527 | |
| 0.003 | 0.756 | 0.06 | Androgen agonist | 0.06 0.042 DBMET03527 | DBMET03527 | |
| 0.019 | 0.773 | 0.13 | Interferon gamma antagonist | 0.13 0.112 DBMET03527 | DBMET03527 | |
| 0.005 | 0.759 | 0.089 | Aminopeptidase I inhibitor | 0.089 0.035 DBMET03527 | DBMET03527 | |
| 0.002 | 0.757 | 0.032 | Purinergic P2Y15 antagonist | 0.032 0.014 DBMET03527 | DBMET03527 | |
| 0 | 0.756 | 0.019 | Carbonic anhydrase X inhibitor | 0.019 0.009 DBMET03527 | DBMET03527 | |
| 0 | 0.756 | 0.019 | Carbonic anhydrase VIII inhibitor | 0.019 0.009 DBMET03527 | DBMET03527 | |
| 0.009 | 0.765 | 0.137 | Toll-Like receptor 2 antagonist | 0.137 0.062 DBMET03527 | DBMET03527 | |
| 0.008 | 0.766 | 0.341 | Spasmolytic | 0.341 0.055 DBMET03527 | DBMET03527 | |
| 0.004 | 0.762 | 0.084 | Phenylalanine 4-hydroxylase inhibitor | 0.084 0.035 DBMET03527 | DBMET03527 | |
| 0.011 | 0.773 | 0.048 | Bombesin 2 receptor antagonist | 0.048 0.036 DBMET03527 | DBMET03527 | |
| 0.001 | 0.763 | 0.039 | Hypoxanthine phosphoribosyltransferase inhibitor | 0.039 0.013 DBMET03527 | DBMET03527 | |
| 0.001 | 0.765 | 0.046 | Arginase inhibitor | 0.046 0.018 DBMET03527 | DBMET03527 | |
| 0.014 | 0.779 | 0.109 | Cyclooxygenase 3 inhibitor | 0.109 0.091 DBMET03527 | DBMET03527 | |
| 0.012 | 0.78 | 0.269 | Antithrombotic | 0.269 0.112 DBMET03527 | DBMET03527 | |
| 0.005 | 0.78 | 0.035 | Glutamate (mGluR8) agonist | 0.035 0.033 DBMET03527 | DBMET03527 | |
| 0.006 | 0.782 | 0.04 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.04 0.034 DBMET03527 | DBMET03527 | |
| 0.002 | 0.779 | 0.048 | NMDA receptor subunit 3B antagonist | 0.048 0.027 DBMET03527 | DBMET03527 | |
| 0.007 | 0.785 | 0.117 | Calcium channel blocker | 0.117 0.091 DBMET03527 | DBMET03527 | |
| 0.035 | 0.818 | 0.419 | Calcium channel activator | 0.419 0.018 DBMET03527 | DBMET03527 | |
| 0.006 | 0.79 | 0.452 | GABA C receptor agonist | 0.452 0.004 DBMET03527 | DBMET03527 | |
| 0.003 | 0.789 | 0.078 | Catalase inhibitor | 0.078 0.049 DBMET03527 | DBMET03527 | |
| 0.008 | 0.798 | 0.2 | Prolactin inhibitor | 0.2 0.009 DBMET03527 | DBMET03527 | |
| 0.013 | 0.804 | 0.286 | Antiobesity | 0.286 0.126 DBMET03527 | DBMET03527 | |
| 0.01 | 0.802 | 0.182 | Cell wall synthesis inhibitor | 0.182 0.039 DBMET03527 | DBMET03527 | |
| 0.003 | 0.797 | 0.103 | Glutamate decarboxylase inhibitor | 0.103 0.028 DBMET03527 | DBMET03527 | |
| 0.009 | 0.803 | 0.099 | Aminopeptidase B inhibitor | 0.099 0.066 DBMET03527 | DBMET03527 | |
| 0.009 | 0.804 | 0.205 | Vasodilator | 0.205 0.101 DBMET03527 | DBMET03527 | |
| 0.015 | 0.811 | 0.216 | Phospholipase C inhibitor | 0.216 0.035 DBMET03527 | DBMET03527 | |
| 0.036 | 0.836 | 0.729 | 5 Hydroxytryptamine release stimulant | 0.729 0.005 DBMET03527 | DBMET03527 | |
| 0.012 | 0.812 | 0.144 | NADH dehydrogenase inhibitor | 0.144 0.019 DBMET03527 | DBMET03527 | |
| 0.005 | 0.806 | 0.06 | Beta 3 adrenoreceptor antagonist | 0.06 0.057 DBMET03527 | DBMET03527 | |
| 0.003 | 0.804 | 0.076 | 5 Hydroxytryptamine 2B agonist | 0.076 0.005 DBMET03527 | DBMET03527 | |
| 0.01 | 0.812 | 0.598 | Aldehyde oxidase inhibitor | 0.598 0.019 DBMET03527 | DBMET03527 | |
| 0.009 | 0.81 | 0.377 | DNA synthesis inhibitor | 0.377 0.025 DBMET03527 | DBMET03527 | |
| 0.002 | 0.804 | 0.056 | Oxytocin agonist | 0.056 0.02 DBMET03527 | DBMET03527 | |
| 0.017 | 0.827 | 0.152 | Adenylate kinase inhibitor | 0.152 0.026 DBMET03527 | DBMET03527 | |
| 0.006 | 0.817 | 0.149 | Arachidonic acid antagonist | 0.149 0.09 DBMET03527 | DBMET03527 | |
| 0.002 | 0.818 | 0.099 | Na+ K+ transporting ATPase inhibitor | 0.099 0.032 DBMET03527 | DBMET03527 | |
| 0.001 | 0.818 | 0.056 | Ornithine carbamoyltransferase inhibitor | 0.056 0.035 DBMET03527 | DBMET03527 | |
| 0.003 | 0.822 | 0.056 | Beta 1 adrenoreceptor antagonist | 0.056 0.039 DBMET03527 | DBMET03527 | |
| 0.01 | 0.83 | 0.077 | Exportin-1 inhibitor | 0.077 0.029 DBMET03527 | DBMET03527 | |
| 0.031 | 0.853 | 0.401 | Tyrosine 3 hydroxylase inhibitor | 0.401 0.008 DBMET03527 | DBMET03527 | |
| 0.005 | 0.83 | 0.104 | Microtubule formation inhibitor | 0.104 0.083 DBMET03527 | DBMET03527 | |
| 0.003 | 0.828 | 0.055 | AMPA 4 receptor antagonist | 0.055 0.012 DBMET03527 | DBMET03527 | |
| 0.004 | 0.831 | 0.103 | Mucolytic | 0.103 0.073 DBMET03527 | DBMET03527 | |
| 0.006 | 0.833 | 0.155 | UDP-glucose 4-epimerase inhibitor | 0.155 0.027 DBMET03527 | DBMET03527 | |
| 0.003 | 0.835 | 0.04 | Membrane dipeptidase inhibitor | 0.04 0.026 DBMET03527 | DBMET03527 | |
| 0.002 | 0.835 | 0.097 | Acyl-CoA dehydrogenase inhibitor | 0.097 0.017 DBMET03527 | DBMET03527 | |
| 0.007 | 0.843 | 0.185 | Succinate dehydrogenase inhibitor | 0.185 0.062 DBMET03527 | DBMET03527 | |
| 0.003 | 0.844 | 0.092 | Expectorant | 0.092 0.079 DBMET03527 | DBMET03527 | |
| 0.002 | 0.844 | 0.069 | Argininosuccinate synthase inhibitor | 0.069 0.031 DBMET03527 | DBMET03527 | |
| 0.005 | 0.85 | 0.272 | GABA C receptor antagonist | 0.272 0.005 DBMET03527 | DBMET03527 | |
| 0.007 | 0.853 | 0.068 | Glutamate (mGluR6) antagonist | 0.068 0.045 DBMET03527 | DBMET03527 | |
| 0.002 | 0.847 | 0.024 | Lysophosphatidic acid receptor 1 agonist | 0.024 0.019 DBMET03527 | DBMET03527 | |
| 0.002 | 0.854 | 0.132 | Carbamoyl phosphate synthetase inhibitor | 0.132 0.014 DBMET03527 | DBMET03527 | |
| 0.001 | 0.857 | 0.082 | Dopamine D5 agonist | 0.082 0.006 DBMET03527 | DBMET03527 | |
| 0.002 | 0.859 | 0.017 | Methylmalonyl-CoA mutase inhibitor | 0.017 0.016 DBMET03527 | DBMET03527 | |
| 0.001 | 0.861 | 0.033 | Fumarate hydratase inhibitor | 0.033 0.025 DBMET03527 | DBMET03527 | |
| 0.003 | 0.865 | 0.142 | Glycine receptor antagonist | 0.142 0.009 DBMET03527 | DBMET03527 | |
| 0.007 | 0.87 | 0.095 | Glutamate dehydrogenase inhibitor | 0.095 0.033 DBMET03527 | DBMET03527 | |
| 0.006 | 0.874 | 0.091 | Glycine receptor agonist | 0.091 0.027 DBMET03527 | DBMET03527 | |
| 0.002 | 0.873 | 0.089 | Mannosidase inhibitor | 0.089 0.007 DBMET03527 | DBMET03527 | |
| 0.007 | 0.883 | 0.1 | Anabolic | 0.1 0.063 DBMET03527 | DBMET03527 | |
| 0.001 | 0.879 | 0.094 | Phosphofructokinase-1 inhibitor | 0.094 0.034 DBMET03527 | DBMET03527 | |
| 0.003 | 0.883 | 0.092 | Alpha-mannosidase inhibitor | 0.092 0.008 DBMET03527 | DBMET03527 | |
| 0.002 | 0.883 | 0.062 | Beta adrenoreceptor antagonist | 0.062 0.051 DBMET03527 | DBMET03527 | |
| 0.006 | 0.888 | 0.178 | Adenylate cyclase stimulant | 0.178 0.027 DBMET03527 | DBMET03527 | |
| 0.003 | 0.894 | 0.047 | Kainate receptor agonist | 0.047 0.018 DBMET03527 | DBMET03527 | |
| 0.001 | 0.898 | 0.044 | GABA uptake inhibitor | 0.044 0.021 DBMET03527 | DBMET03527 | |
| 0.007 | 0.905 | 0.112 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.112 0.044 DBMET03527 | DBMET03527 | |
| 0.003 | 0.907 | 0.084 | GABA B receptor agonist | 0.084 0.034 DBMET03527 | DBMET03527 | |
| 0.002 | 0.91 | 0.051 | GABA B receptor antagonist | 0.051 0.018 DBMET03527 | DBMET03527 | |
| 0.004 | 0.92 | 0.103 | DOPA decarboxylase inhibitor | 0.103 0.07 DBMET03527 | DBMET03527 | |
| 0.004 | 0.921 | 0.055 | Phenylethanolamine N methyltransferase inhibitor | 0.055 0.01 DBMET03527 | DBMET03527 | |
| 0.004 | 0.923 | 0.231 | Antibacterial | 0.231 0.195 DBMET03527 | DBMET03527 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |